JP2021523712A - 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ(rmva)ワクチン及びその調製方法 - Google Patents
安定性が改善された遺伝子組み換え組換えワクシニアアンカラ(rmva)ワクチン及びその調製方法 Download PDFInfo
- Publication number
- JP2021523712A JP2021523712A JP2020563659A JP2020563659A JP2021523712A JP 2021523712 A JP2021523712 A JP 2021523712A JP 2020563659 A JP2020563659 A JP 2020563659A JP 2020563659 A JP2020563659 A JP 2020563659A JP 2021523712 A JP2021523712 A JP 2021523712A
- Authority
- JP
- Japan
- Prior art keywords
- ser
- pro
- thr
- ala
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 39
- 206010046865 Vaccinia virus infection Diseases 0.000 title claims abstract description 15
- 208000007089 vaccinia Diseases 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title description 2
- 108091007433 antigens Proteins 0.000 claims abstract description 123
- 102000036639 antigens Human genes 0.000 claims abstract description 123
- 239000000427 antigen Substances 0.000 claims abstract description 112
- 238000003780 insertion Methods 0.000 claims abstract description 68
- 230000037431 insertion Effects 0.000 claims abstract description 68
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 54
- 230000035772 mutation Effects 0.000 claims abstract description 46
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000012634 fragment Substances 0.000 claims abstract description 24
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims abstract description 20
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000000890 antigenic effect Effects 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 230000004048 modification Effects 0.000 claims abstract description 13
- 238000012986 modification Methods 0.000 claims abstract description 13
- 108020004705 Codon Proteins 0.000 claims abstract description 12
- 238000005457 optimization Methods 0.000 claims abstract description 11
- 229940104302 cytosine Drugs 0.000 claims abstract description 10
- 241001212582 Ancara Species 0.000 claims abstract description 8
- 241000701022 Cytomegalovirus Species 0.000 claims description 52
- 230000014509 gene expression Effects 0.000 claims description 49
- 230000003612 virological effect Effects 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 230000002068 genetic effect Effects 0.000 claims description 12
- 230000004927 fusion Effects 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 7
- 102000037865 fusion proteins Human genes 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 56
- 108090000623 proteins and genes Proteins 0.000 description 102
- 238000003752 polymerase chain reaction Methods 0.000 description 99
- 238000001262 western blot Methods 0.000 description 97
- 239000000047 product Substances 0.000 description 70
- 210000004027 cell Anatomy 0.000 description 51
- 238000004458 analytical method Methods 0.000 description 50
- 208000015181 infectious disease Diseases 0.000 description 49
- 239000013642 negative control Substances 0.000 description 49
- 239000000523 sample Substances 0.000 description 47
- 102000003886 Glycoproteins Human genes 0.000 description 46
- 108090000288 Glycoproteins Proteins 0.000 description 46
- 239000011543 agarose gel Substances 0.000 description 46
- 238000011068 loading method Methods 0.000 description 46
- 102000004169 proteins and genes Human genes 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 37
- 206010072219 Mevalonic aciduria Diseases 0.000 description 34
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 34
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 25
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 24
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 21
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 21
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 21
- 108010079364 N-glycylalanine Proteins 0.000 description 18
- QSKCKTUQPICLSO-AVGNSLFASA-N Pro-Arg-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O QSKCKTUQPICLSO-AVGNSLFASA-N 0.000 description 18
- OLFOOYQTTQSSRK-UNQGMJICSA-N Thr-Pro-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OLFOOYQTTQSSRK-UNQGMJICSA-N 0.000 description 18
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 18
- 108010044940 alanylglutamine Proteins 0.000 description 18
- 108010070643 prolylglutamic acid Proteins 0.000 description 18
- 108010026333 seryl-proline Proteins 0.000 description 18
- 108091033319 polynucleotide Proteins 0.000 description 17
- 102000040430 polynucleotide Human genes 0.000 description 17
- 239000002157 polynucleotide Substances 0.000 description 17
- 108010061238 threonyl-glycine Proteins 0.000 description 17
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 15
- 241000880493 Leptailurus serval Species 0.000 description 15
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 15
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 15
- 108010017391 lysylvaline Proteins 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- KIEICAOUSNYOLM-NRPADANISA-N Glu-Val-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KIEICAOUSNYOLM-NRPADANISA-N 0.000 description 12
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 12
- GLYJPWIRLBAIJH-UHFFFAOYSA-N Ile-Lys-Pro Natural products CCC(C)C(N)C(=O)NC(CCCCN)C(=O)N1CCCC1C(O)=O GLYJPWIRLBAIJH-UHFFFAOYSA-N 0.000 description 12
- ILJREDZFPHTUIE-GUBZILKMSA-N Leu-Asp-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ILJREDZFPHTUIE-GUBZILKMSA-N 0.000 description 12
- KWLWZYMNUZJKMZ-IHRRRGAJSA-N Leu-Pro-Leu Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O KWLWZYMNUZJKMZ-IHRRRGAJSA-N 0.000 description 12
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 12
- MOVJSUIKUNCVMG-ZLUOBGJFSA-N Ser-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)O MOVJSUIKUNCVMG-ZLUOBGJFSA-N 0.000 description 12
- PUEWAXRPXOEQOW-HJGDQZAQSA-N Thr-Met-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(O)=O PUEWAXRPXOEQOW-HJGDQZAQSA-N 0.000 description 12
- XWYUBUYQMOUFRQ-IFFSRLJSSA-N Val-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N)O XWYUBUYQMOUFRQ-IFFSRLJSSA-N 0.000 description 12
- 108010060035 arginylproline Proteins 0.000 description 12
- 108010085325 histidylproline Proteins 0.000 description 12
- 230000005847 immunogenicity Effects 0.000 description 12
- 108010057821 leucylproline Proteins 0.000 description 12
- 230000005867 T cell response Effects 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- BRRPVTUFESPTCP-ACZMJKKPSA-N Asp-Ser-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O BRRPVTUFESPTCP-ACZMJKKPSA-N 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- XAGIMRPOEJSYER-CIUDSAMLSA-N Ala-Cys-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N XAGIMRPOEJSYER-CIUDSAMLSA-N 0.000 description 9
- LJFNNUBZSZCZFN-WHFBIAKZSA-N Ala-Gly-Cys Chemical compound N[C@@H](C)C(=O)NCC(=O)N[C@@H](CS)C(=O)O LJFNNUBZSZCZFN-WHFBIAKZSA-N 0.000 description 9
- GSHKMNKPMLXSQW-KBIXCLLPSA-N Ala-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C)N GSHKMNKPMLXSQW-KBIXCLLPSA-N 0.000 description 9
- RZZMZYZXNJRPOJ-BJDJZHNGSA-N Ala-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C)N RZZMZYZXNJRPOJ-BJDJZHNGSA-N 0.000 description 9
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 9
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 9
- QOIGKCBMXUCDQU-KDXUFGMBSA-N Ala-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N)O QOIGKCBMXUCDQU-KDXUFGMBSA-N 0.000 description 9
- TVUFMYKTYXTRPY-HERUPUMHSA-N Ala-Trp-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(O)=O TVUFMYKTYXTRPY-HERUPUMHSA-N 0.000 description 9
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 9
- DPNHSNLIULPOBH-GUBZILKMSA-N Arg-Asn-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N DPNHSNLIULPOBH-GUBZILKMSA-N 0.000 description 9
- AQPVUEJJARLJHB-BQBZGAKWSA-N Arg-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N AQPVUEJJARLJHB-BQBZGAKWSA-N 0.000 description 9
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 9
- WOZDCBHUGJVJPL-AVGNSLFASA-N Arg-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WOZDCBHUGJVJPL-AVGNSLFASA-N 0.000 description 9
- GIQCDTKOIPUDSG-GARJFASQSA-N Asn-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N)C(=O)O GIQCDTKOIPUDSG-GARJFASQSA-N 0.000 description 9
- XWSIYTYNLKCLJB-CIUDSAMLSA-N Asp-Lys-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O XWSIYTYNLKCLJB-CIUDSAMLSA-N 0.000 description 9
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 9
- 241000287828 Gallus gallus Species 0.000 description 9
- JSYULGSPLTZDHM-NRPADANISA-N Gln-Ala-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O JSYULGSPLTZDHM-NRPADANISA-N 0.000 description 9
- DTMLKCYOQKZXKZ-HJGDQZAQSA-N Gln-Arg-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DTMLKCYOQKZXKZ-HJGDQZAQSA-N 0.000 description 9
- RGAOLBZBLOJUTP-GRLWGSQLSA-N Gln-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CCC(=O)N)N RGAOLBZBLOJUTP-GRLWGSQLSA-N 0.000 description 9
- BZULIEARJFRINC-IHRRRGAJSA-N Gln-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N BZULIEARJFRINC-IHRRRGAJSA-N 0.000 description 9
- UWMDGPFFTKDUIY-HJGDQZAQSA-N Gln-Pro-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWMDGPFFTKDUIY-HJGDQZAQSA-N 0.000 description 9
- GJLXZITZLUUXMJ-NHCYSSNCSA-N Gln-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)N)N GJLXZITZLUUXMJ-NHCYSSNCSA-N 0.000 description 9
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 9
- KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 description 9
- UMZHHILWZBFPGL-LOKLDPHHSA-N Glu-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O UMZHHILWZBFPGL-LOKLDPHHSA-N 0.000 description 9
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 9
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 9
- DVHGLDYMGWTYKW-GUBZILKMSA-N His-Gln-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O DVHGLDYMGWTYKW-GUBZILKMSA-N 0.000 description 9
- JIUYRPFQJJRSJB-QWRGUYRKSA-N His-His-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(O)=O)C1=CN=CN1 JIUYRPFQJJRSJB-QWRGUYRKSA-N 0.000 description 9
- IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 description 9
- HTDRTKMNJRRYOJ-SIUGBPQLSA-N Ile-Gln-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HTDRTKMNJRRYOJ-SIUGBPQLSA-N 0.000 description 9
- WZDCVAWMBUNDDY-KBIXCLLPSA-N Ile-Glu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)O)N WZDCVAWMBUNDDY-KBIXCLLPSA-N 0.000 description 9
- KLBVGHCGHUNHEA-BJDJZHNGSA-N Ile-Leu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O)N KLBVGHCGHUNHEA-BJDJZHNGSA-N 0.000 description 9
- ZUPJCJINYQISSN-XUXIUFHCSA-N Ile-Met-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N ZUPJCJINYQISSN-XUXIUFHCSA-N 0.000 description 9
- DLEBSGAVWRPTIX-PEDHHIEDSA-N Ile-Val-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)[C@@H](C)CC DLEBSGAVWRPTIX-PEDHHIEDSA-N 0.000 description 9
- HBJZFCIVFIBNSV-DCAQKATOSA-N Leu-Arg-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O HBJZFCIVFIBNSV-DCAQKATOSA-N 0.000 description 9
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 9
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 9
- BABSVXFGKFLIGW-UWVGGRQHSA-N Leu-Gly-Arg Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N BABSVXFGKFLIGW-UWVGGRQHSA-N 0.000 description 9
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 9
- BJWKOATWNQJPSK-SRVKXCTJSA-N Leu-Met-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N BJWKOATWNQJPSK-SRVKXCTJSA-N 0.000 description 9
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 9
- VHNOAIFVYUQOOY-XUXIUFHCSA-N Lys-Arg-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VHNOAIFVYUQOOY-XUXIUFHCSA-N 0.000 description 9
- BYEBKXRNDLTGFW-CIUDSAMLSA-N Lys-Cys-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O BYEBKXRNDLTGFW-CIUDSAMLSA-N 0.000 description 9
- DTUZCYRNEJDKSR-NHCYSSNCSA-N Lys-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN DTUZCYRNEJDKSR-NHCYSSNCSA-N 0.000 description 9
- YDDDRTIPNTWGIG-SRVKXCTJSA-N Lys-Lys-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O YDDDRTIPNTWGIG-SRVKXCTJSA-N 0.000 description 9
- DNWBUCHHMRQWCZ-GUBZILKMSA-N Lys-Ser-Gln Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DNWBUCHHMRQWCZ-GUBZILKMSA-N 0.000 description 9
- JMNRXRPBHFGXQX-GUBZILKMSA-N Lys-Ser-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JMNRXRPBHFGXQX-GUBZILKMSA-N 0.000 description 9
- CFRRIZLGFGJEDB-SRVKXCTJSA-N Met-His-Gln Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(O)=O CFRRIZLGFGJEDB-SRVKXCTJSA-N 0.000 description 9
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 9
- ZVRJWDUPIDMHDN-ULQDDVLXSA-N Phe-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 ZVRJWDUPIDMHDN-ULQDDVLXSA-N 0.000 description 9
- CYQQWUPHIZVCNY-GUBZILKMSA-N Pro-Arg-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CYQQWUPHIZVCNY-GUBZILKMSA-N 0.000 description 9
- YFNOUBWUIIJQHF-LPEHRKFASA-N Pro-Asp-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O YFNOUBWUIIJQHF-LPEHRKFASA-N 0.000 description 9
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 9
- CFVRJNZJQHDQPP-CYDGBPFRSA-N Pro-Ile-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 CFVRJNZJQHDQPP-CYDGBPFRSA-N 0.000 description 9
- SWRNSCMUXRLHCR-ULQDDVLXSA-N Pro-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 SWRNSCMUXRLHCR-ULQDDVLXSA-N 0.000 description 9
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 9
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 9
- GBUNEGKQPSAMNK-QTKMDUPCSA-N Pro-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2)O GBUNEGKQPSAMNK-QTKMDUPCSA-N 0.000 description 9
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 9
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 9
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 description 9
- RNFKSBPHLTZHLU-WHFBIAKZSA-N Ser-Cys-Gly Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N)O RNFKSBPHLTZHLU-WHFBIAKZSA-N 0.000 description 9
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 description 9
- VQBCMLMPEWPUTB-ACZMJKKPSA-N Ser-Glu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VQBCMLMPEWPUTB-ACZMJKKPSA-N 0.000 description 9
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 9
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 9
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 9
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 9
- IRKWVRSEQFTGGV-VEVYYDQMSA-N Thr-Asn-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IRKWVRSEQFTGGV-VEVYYDQMSA-N 0.000 description 9
- YJCVECXVYHZOBK-KNZXXDILSA-N Thr-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H]([C@@H](C)O)N YJCVECXVYHZOBK-KNZXXDILSA-N 0.000 description 9
- MUAFDCVOHYAFNG-RCWTZXSCSA-N Thr-Pro-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MUAFDCVOHYAFNG-RCWTZXSCSA-N 0.000 description 9
- GVMXJJAJLIEASL-ZJDVBMNYSA-N Thr-Pro-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVMXJJAJLIEASL-ZJDVBMNYSA-N 0.000 description 9
- QYDKSNXSBXZPFK-ZJDVBMNYSA-N Thr-Thr-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYDKSNXSBXZPFK-ZJDVBMNYSA-N 0.000 description 9
- GITNQBVCEQBDQC-KKUMJFAQSA-N Tyr-Lys-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O GITNQBVCEQBDQC-KKUMJFAQSA-N 0.000 description 9
- JOQSQZFKFYJKKJ-GUBZILKMSA-N Val-Arg-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N JOQSQZFKFYJKKJ-GUBZILKMSA-N 0.000 description 9
- PFNZJEPSCBAVGX-CYDGBPFRSA-N Val-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N PFNZJEPSCBAVGX-CYDGBPFRSA-N 0.000 description 9
- BYOHPUZJVXWHAE-BYULHYEWSA-N Val-Asn-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N BYOHPUZJVXWHAE-BYULHYEWSA-N 0.000 description 9
- ISERLACIZUGCDX-ZKWXMUAHSA-N Val-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N ISERLACIZUGCDX-ZKWXMUAHSA-N 0.000 description 9
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 9
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 9
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 9
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 9
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 9
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 9
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 description 9
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 9
- 108010003700 lysyl aspartic acid Proteins 0.000 description 9
- 108010073101 phenylalanylleucine Proteins 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 108010077112 prolyl-proline Proteins 0.000 description 9
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 9
- 108010053725 prolylvaline Proteins 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 8
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 8
- 108010058607 HLA-B Antigens Proteins 0.000 description 8
- MMAPOBOTRUVNKJ-ZLUOBGJFSA-N Ser-Asp-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CO)N)C(=O)O MMAPOBOTRUVNKJ-ZLUOBGJFSA-N 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 230000010473 stable expression Effects 0.000 description 8
- 108010075704 HLA-A Antigens Proteins 0.000 description 7
- LNDVNHOSZQPJGI-AVGNSLFASA-N His-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CN=CN1 LNDVNHOSZQPJGI-AVGNSLFASA-N 0.000 description 7
- AHEBIAHEZWQVHB-QTKMDUPCSA-N His-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O AHEBIAHEZWQVHB-QTKMDUPCSA-N 0.000 description 7
- 101150025093 IE2 gene Proteins 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 6
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 6
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 6
- MAISCYVJLBBRNU-DCAQKATOSA-N Arg-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N MAISCYVJLBBRNU-DCAQKATOSA-N 0.000 description 6
- YBZMTKUDWXZLIX-UWVGGRQHSA-N Arg-Leu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YBZMTKUDWXZLIX-UWVGGRQHSA-N 0.000 description 6
- VJTWLBMESLDOMK-WDSKDSINSA-N Asn-Gln-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O VJTWLBMESLDOMK-WDSKDSINSA-N 0.000 description 6
- RAKKBBHMTJSXOY-XVYDVKMFSA-N Asn-His-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(O)=O RAKKBBHMTJSXOY-XVYDVKMFSA-N 0.000 description 6
- QEQVUHQQYDZUEN-GUBZILKMSA-N Asn-His-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N QEQVUHQQYDZUEN-GUBZILKMSA-N 0.000 description 6
- LTDGPJKGJDIBQD-LAEOZQHASA-N Asn-Val-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LTDGPJKGJDIBQD-LAEOZQHASA-N 0.000 description 6
- ZELQAFZSJOBEQS-ACZMJKKPSA-N Asp-Asn-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZELQAFZSJOBEQS-ACZMJKKPSA-N 0.000 description 6
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 6
- KLLFLHBKSJAUMZ-ACZMJKKPSA-N Cys-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N KLLFLHBKSJAUMZ-ACZMJKKPSA-N 0.000 description 6
- HBHMVBGGHDMPBF-GARJFASQSA-N Cys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N HBHMVBGGHDMPBF-GARJFASQSA-N 0.000 description 6
- IQXSTXKVEMRMMB-XAVMHZPKSA-N Cys-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N)O IQXSTXKVEMRMMB-XAVMHZPKSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- MFJAPSYJQJCQDN-BQBZGAKWSA-N Gln-Gly-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O MFJAPSYJQJCQDN-BQBZGAKWSA-N 0.000 description 6
- MSHXWFKYXJTLEZ-CIUDSAMLSA-N Gln-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MSHXWFKYXJTLEZ-CIUDSAMLSA-N 0.000 description 6
- IESFZVCAVACGPH-PEFMBERDSA-N Glu-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O IESFZVCAVACGPH-PEFMBERDSA-N 0.000 description 6
- FBEJIDRSQCGFJI-GUBZILKMSA-N Glu-Leu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FBEJIDRSQCGFJI-GUBZILKMSA-N 0.000 description 6
- HZISRJBYZAODRV-XQXXSGGOSA-N Glu-Thr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O HZISRJBYZAODRV-XQXXSGGOSA-N 0.000 description 6
- UTYGDAHJBBDPBA-BYULHYEWSA-N Gly-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN UTYGDAHJBBDPBA-BYULHYEWSA-N 0.000 description 6
- VHHYJBSXXMPQGZ-AVGNSLFASA-N His-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N VHHYJBSXXMPQGZ-AVGNSLFASA-N 0.000 description 6
- WKEABZIITNXXQZ-CIUDSAMLSA-N His-Ser-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N WKEABZIITNXXQZ-CIUDSAMLSA-N 0.000 description 6
- PWDSHAAAFXISLE-SXTJYALSSA-N Ile-Ile-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O PWDSHAAAFXISLE-SXTJYALSSA-N 0.000 description 6
- HUWYGQOISIJNMK-SIGLWIIPSA-N Ile-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HUWYGQOISIJNMK-SIGLWIIPSA-N 0.000 description 6
- PNTWNAXGBOZMBO-MNXVOIDGSA-N Ile-Lys-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N PNTWNAXGBOZMBO-MNXVOIDGSA-N 0.000 description 6
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 6
- DLCXCECTCPKKCD-GUBZILKMSA-N Leu-Gln-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DLCXCECTCPKKCD-GUBZILKMSA-N 0.000 description 6
- OHZIZVWQXJPBJS-IXOXFDKPSA-N Leu-His-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OHZIZVWQXJPBJS-IXOXFDKPSA-N 0.000 description 6
- KXCMQWMNYQOAKA-SRVKXCTJSA-N Leu-Met-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N KXCMQWMNYQOAKA-SRVKXCTJSA-N 0.000 description 6
- XXXXOVFBXRERQL-ULQDDVLXSA-N Leu-Pro-Phe Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XXXXOVFBXRERQL-ULQDDVLXSA-N 0.000 description 6
- UQJOKDAYFULYIX-AVGNSLFASA-N Lys-Pro-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 UQJOKDAYFULYIX-AVGNSLFASA-N 0.000 description 6
- OHXUUQDOBQKSNB-AVGNSLFASA-N Lys-Val-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OHXUUQDOBQKSNB-AVGNSLFASA-N 0.000 description 6
- SDTSLIMYROCDNS-FXQIFTODSA-N Met-Cys-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O SDTSLIMYROCDNS-FXQIFTODSA-N 0.000 description 6
- DGNZGCQSVGGYJS-BQBZGAKWSA-N Met-Gly-Asp Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O DGNZGCQSVGGYJS-BQBZGAKWSA-N 0.000 description 6
- LNXGEYIEEUZGGH-JYJNAYRXSA-N Met-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)CC1=CC=CC=C1 LNXGEYIEEUZGGH-JYJNAYRXSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- ACJULKNZOCRWEI-ULQDDVLXSA-N Phe-Met-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O ACJULKNZOCRWEI-ULQDDVLXSA-N 0.000 description 6
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 6
- VJLJGKQAOQJXJG-CIUDSAMLSA-N Pro-Asp-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VJLJGKQAOQJXJG-CIUDSAMLSA-N 0.000 description 6
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 6
- RYJRPPUATSKNAY-STECZYCISA-N Pro-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@@H]2CCCN2 RYJRPPUATSKNAY-STECZYCISA-N 0.000 description 6
- MCWHYUWXVNRXFV-RWMBFGLXSA-N Pro-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 MCWHYUWXVNRXFV-RWMBFGLXSA-N 0.000 description 6
- FKYKZHOKDOPHSA-DCAQKATOSA-N Pro-Leu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FKYKZHOKDOPHSA-DCAQKATOSA-N 0.000 description 6
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 6
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 6
- JURQXQBJKUHGJS-UHFFFAOYSA-N Ser-Ser-Ser-Ser Chemical compound OCC(N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CO)C(O)=O JURQXQBJKUHGJS-UHFFFAOYSA-N 0.000 description 6
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 6
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 6
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 6
- OWQKBXKXZFRRQL-XGEHTFHBSA-N Thr-Met-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CS)C(=O)O)N)O OWQKBXKXZFRRQL-XGEHTFHBSA-N 0.000 description 6
- DXYWRYQRKPIGGU-BPNCWPANSA-N Tyr-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DXYWRYQRKPIGGU-BPNCWPANSA-N 0.000 description 6
- ITDWWLTTWRRLCC-KJEVXHAQSA-N Tyr-Thr-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ITDWWLTTWRRLCC-KJEVXHAQSA-N 0.000 description 6
- VHRLUTIMTDOVCG-PEDHHIEDSA-N Val-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](C(C)C)N VHRLUTIMTDOVCG-PEDHHIEDSA-N 0.000 description 6
- AJNUKMZFHXUBMK-GUBZILKMSA-N Val-Ser-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AJNUKMZFHXUBMK-GUBZILKMSA-N 0.000 description 6
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 6
- 108010028939 alanyl-alanyl-lysyl-alanine Proteins 0.000 description 6
- 108010045350 alanyl-tyrosyl-alanine Proteins 0.000 description 6
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 108010078144 glutaminyl-glycine Proteins 0.000 description 6
- 108010040030 histidinoalanine Proteins 0.000 description 6
- 108010031719 prolyl-serine Proteins 0.000 description 6
- 108010029020 prolylglycine Proteins 0.000 description 6
- 108010090894 prolylleucine Proteins 0.000 description 6
- 238000002864 sequence alignment Methods 0.000 description 6
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 5
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- RCOUFINCYASMDN-GUBZILKMSA-N Ser-Val-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O RCOUFINCYASMDN-GUBZILKMSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 101150089187 IE1 gene Proteins 0.000 description 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- PCDUALPXEOKZPE-DXCABUDRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O PCDUALPXEOKZPE-DXCABUDRSA-N 0.000 description 3
- JBFQOLHAGBKPTP-NZATWWQASA-N (2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](N)CCCCN JBFQOLHAGBKPTP-NZATWWQASA-N 0.000 description 3
- AAQGRPOPTAUUBM-ZLUOBGJFSA-N Ala-Ala-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O AAQGRPOPTAUUBM-ZLUOBGJFSA-N 0.000 description 3
- XYKDZXKKYOOTGC-FXQIFTODSA-N Ala-Cys-Met Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)O)N XYKDZXKKYOOTGC-FXQIFTODSA-N 0.000 description 3
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 3
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 3
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 3
- LBYMZCVBOKYZNS-CIUDSAMLSA-N Ala-Leu-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O LBYMZCVBOKYZNS-CIUDSAMLSA-N 0.000 description 3
- LDLSENBXQNDTPB-DCAQKATOSA-N Ala-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LDLSENBXQNDTPB-DCAQKATOSA-N 0.000 description 3
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 3
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 3
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 3
- AENHOIXXHKNIQL-AUTRQRHGSA-N Ala-Tyr-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]([NH3+])C)CC1=CC=C(O)C=C1 AENHOIXXHKNIQL-AUTRQRHGSA-N 0.000 description 3
- JPOQZCHGOTWRTM-FQPOAREZSA-N Ala-Tyr-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPOQZCHGOTWRTM-FQPOAREZSA-N 0.000 description 3
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 3
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 3
- VBFJESQBIWCWRL-DCAQKATOSA-N Arg-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VBFJESQBIWCWRL-DCAQKATOSA-N 0.000 description 3
- HJVGMOYJDDXLMI-AVGNSLFASA-N Arg-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N HJVGMOYJDDXLMI-AVGNSLFASA-N 0.000 description 3
- QPOARHANPULOTM-GMOBBJLQSA-N Arg-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N QPOARHANPULOTM-GMOBBJLQSA-N 0.000 description 3
- SQKPKIJVWHAWNF-DCAQKATOSA-N Arg-Asp-Lys Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O SQKPKIJVWHAWNF-DCAQKATOSA-N 0.000 description 3
- XLWSGICNBZGYTA-CIUDSAMLSA-N Arg-Glu-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XLWSGICNBZGYTA-CIUDSAMLSA-N 0.000 description 3
- AGVNTAUPLWIQEN-ZPFDUUQYSA-N Arg-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AGVNTAUPLWIQEN-ZPFDUUQYSA-N 0.000 description 3
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 3
- QTAIIXQCOPUNBQ-QXEWZRGKSA-N Arg-Val-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QTAIIXQCOPUNBQ-QXEWZRGKSA-N 0.000 description 3
- GNKVBRYFXYWXAB-WDSKDSINSA-N Asn-Glu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O GNKVBRYFXYWXAB-WDSKDSINSA-N 0.000 description 3
- OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 description 3
- JWKDQOORUCYUIW-ZPFDUUQYSA-N Asn-Lys-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JWKDQOORUCYUIW-ZPFDUUQYSA-N 0.000 description 3
- NNDSLVWAQAUPPP-GUBZILKMSA-N Asn-Met-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)N)N NNDSLVWAQAUPPP-GUBZILKMSA-N 0.000 description 3
- WUQXMTITJLFXAU-JIOCBJNQSA-N Asn-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N)O WUQXMTITJLFXAU-JIOCBJNQSA-N 0.000 description 3
- GBAWQWASNGUNQF-ZLUOBGJFSA-N Asp-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N GBAWQWASNGUNQF-ZLUOBGJFSA-N 0.000 description 3
- SBHUBSDEZQFJHJ-CIUDSAMLSA-N Asp-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O SBHUBSDEZQFJHJ-CIUDSAMLSA-N 0.000 description 3
- RYKWOUUZJFSJOH-FXQIFTODSA-N Asp-Gln-Glu Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N RYKWOUUZJFSJOH-FXQIFTODSA-N 0.000 description 3
- XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 3
- GHODABZPVZMWCE-FXQIFTODSA-N Asp-Glu-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GHODABZPVZMWCE-FXQIFTODSA-N 0.000 description 3
- YFSLJHLQOALGSY-ZPFDUUQYSA-N Asp-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N YFSLJHLQOALGSY-ZPFDUUQYSA-N 0.000 description 3
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 3
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- XGIAHEUULGOZHH-GUBZILKMSA-N Cys-Arg-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N XGIAHEUULGOZHH-GUBZILKMSA-N 0.000 description 3
- ZMWOJVAXTOUHAP-ZKWXMUAHSA-N Cys-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N ZMWOJVAXTOUHAP-ZKWXMUAHSA-N 0.000 description 3
- ABLQPNMKLMFDQU-BIIVOSGPSA-N Cys-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CS)N)C(=O)O ABLQPNMKLMFDQU-BIIVOSGPSA-N 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- MLZRSFQRBDNJON-GUBZILKMSA-N Gln-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MLZRSFQRBDNJON-GUBZILKMSA-N 0.000 description 3
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 description 3
- NSNUZSPSADIMJQ-WDSKDSINSA-N Gln-Gly-Asp Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O NSNUZSPSADIMJQ-WDSKDSINSA-N 0.000 description 3
- MTCXQQINVAFZKW-MNXVOIDGSA-N Gln-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MTCXQQINVAFZKW-MNXVOIDGSA-N 0.000 description 3
- HHQCBFGKQDMWSP-GUBZILKMSA-N Gln-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HHQCBFGKQDMWSP-GUBZILKMSA-N 0.000 description 3
- LURQDGKYBFWWJA-MNXVOIDGSA-N Gln-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N LURQDGKYBFWWJA-MNXVOIDGSA-N 0.000 description 3
- UTOQQOMEJDPDMX-ACZMJKKPSA-N Gln-Ser-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O UTOQQOMEJDPDMX-ACZMJKKPSA-N 0.000 description 3
- DUGYCMAIAKAQPB-GLLZPBPUSA-N Gln-Thr-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DUGYCMAIAKAQPB-GLLZPBPUSA-N 0.000 description 3
- RLZBLVSJDFHDBL-KBIXCLLPSA-N Glu-Ala-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RLZBLVSJDFHDBL-KBIXCLLPSA-N 0.000 description 3
- RDDSZZJOKDVPAE-ACZMJKKPSA-N Glu-Asn-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDDSZZJOKDVPAE-ACZMJKKPSA-N 0.000 description 3
- ZJICFHQSPWFBKP-AVGNSLFASA-N Glu-Asn-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZJICFHQSPWFBKP-AVGNSLFASA-N 0.000 description 3
- JVSBYEDSSRZQGV-GUBZILKMSA-N Glu-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O JVSBYEDSSRZQGV-GUBZILKMSA-N 0.000 description 3
- HJIFPJUEOGZWRI-GUBZILKMSA-N Glu-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N HJIFPJUEOGZWRI-GUBZILKMSA-N 0.000 description 3
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 description 3
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 3
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 3
- PHONAZGUEGIOEM-GLLZPBPUSA-N Glu-Glu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PHONAZGUEGIOEM-GLLZPBPUSA-N 0.000 description 3
- AIGROOHQXCACHL-WDSKDSINSA-N Glu-Gly-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O AIGROOHQXCACHL-WDSKDSINSA-N 0.000 description 3
- YVYVMJNUENBOOL-KBIXCLLPSA-N Glu-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N YVYVMJNUENBOOL-KBIXCLLPSA-N 0.000 description 3
- VGUYMZGLJUJRBV-YVNDNENWSA-N Glu-Ile-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O VGUYMZGLJUJRBV-YVNDNENWSA-N 0.000 description 3
- GRHXUHCFENOCOS-ZPFDUUQYSA-N Glu-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)O)N GRHXUHCFENOCOS-ZPFDUUQYSA-N 0.000 description 3
- MFNUFCFRAZPJFW-JYJNAYRXSA-N Glu-Lys-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFNUFCFRAZPJFW-JYJNAYRXSA-N 0.000 description 3
- SOEPMWQCTJITPZ-SRVKXCTJSA-N Glu-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N SOEPMWQCTJITPZ-SRVKXCTJSA-N 0.000 description 3
- HOIPREWORBVRLD-XIRDDKMYSA-N Glu-Met-Trp Chemical compound CSCC[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O HOIPREWORBVRLD-XIRDDKMYSA-N 0.000 description 3
- YTRBQAQSUDSIQE-FHWLQOOXSA-N Glu-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 YTRBQAQSUDSIQE-FHWLQOOXSA-N 0.000 description 3
- GMVCSRBOSIUTFC-FXQIFTODSA-N Glu-Ser-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMVCSRBOSIUTFC-FXQIFTODSA-N 0.000 description 3
- HMJULNMJWOZNFI-XHNCKOQMSA-N Glu-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N)C(=O)O HMJULNMJWOZNFI-XHNCKOQMSA-N 0.000 description 3
- MFYLRRCYBBJYPI-JYJNAYRXSA-N Glu-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O MFYLRRCYBBJYPI-JYJNAYRXSA-N 0.000 description 3
- RLFSBAPJTYKSLG-WHFBIAKZSA-N Gly-Ala-Asp Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O RLFSBAPJTYKSLG-WHFBIAKZSA-N 0.000 description 3
- VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 description 3
- MZZSCEANQDPJER-ONGXEEELSA-N Gly-Ala-Phe Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MZZSCEANQDPJER-ONGXEEELSA-N 0.000 description 3
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 3
- IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 3
- KAJAOGBVWCYGHZ-JTQLQIEISA-N Gly-Gly-Phe Chemical compound [NH3+]CC(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KAJAOGBVWCYGHZ-JTQLQIEISA-N 0.000 description 3
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 3
- DCRODRAURLJOFY-XPUUQOCRSA-N His-Ala-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)NCC(O)=O DCRODRAURLJOFY-XPUUQOCRSA-N 0.000 description 3
- STWGDDDFLUFCCA-GVXVVHGQSA-N His-Glu-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O STWGDDDFLUFCCA-GVXVVHGQSA-N 0.000 description 3
- VTZYMXGGXOFBMX-DJFWLOJKSA-N His-Ile-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O VTZYMXGGXOFBMX-DJFWLOJKSA-N 0.000 description 3
- MFQVZYSPCIZFMR-MGHWNKPDSA-N His-Ile-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N MFQVZYSPCIZFMR-MGHWNKPDSA-N 0.000 description 3
- ABCCKUZDWMERKT-AVGNSLFASA-N His-Pro-Met Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(O)=O ABCCKUZDWMERKT-AVGNSLFASA-N 0.000 description 3
- IXQGOKWTQPCIQM-YJRXYDGGSA-N His-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)O IXQGOKWTQPCIQM-YJRXYDGGSA-N 0.000 description 3
- DCQMJRSOGCYKTR-GHCJXIJMSA-N Ile-Asp-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O DCQMJRSOGCYKTR-GHCJXIJMSA-N 0.000 description 3
- GYAFMRQGWHXMII-IUKAMOBKSA-N Ile-Asp-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N GYAFMRQGWHXMII-IUKAMOBKSA-N 0.000 description 3
- JLWLMGADIQFKRD-QSFUFRPTSA-N Ile-His-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CN=CN1 JLWLMGADIQFKRD-QSFUFRPTSA-N 0.000 description 3
- CSQNHSGHAPRGPQ-YTFOTSKYSA-N Ile-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)O)N CSQNHSGHAPRGPQ-YTFOTSKYSA-N 0.000 description 3
- ADDYYRVQQZFIMW-MNXVOIDGSA-N Ile-Lys-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ADDYYRVQQZFIMW-MNXVOIDGSA-N 0.000 description 3
- CAHCWMVNBZJVAW-NAKRPEOUSA-N Ile-Pro-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O)N CAHCWMVNBZJVAW-NAKRPEOUSA-N 0.000 description 3
- PELCGFMHLZXWBQ-BJDJZHNGSA-N Ile-Ser-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)N PELCGFMHLZXWBQ-BJDJZHNGSA-N 0.000 description 3
- RMJWFINHACYKJI-SIUGBPQLSA-N Ile-Tyr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RMJWFINHACYKJI-SIUGBPQLSA-N 0.000 description 3
- RQZFWBLDTBDEOF-RNJOBUHISA-N Ile-Val-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N RQZFWBLDTBDEOF-RNJOBUHISA-N 0.000 description 3
- 108010065920 Insulin Lispro Proteins 0.000 description 3
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 3
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 3
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 3
- GZAUZBUKDXYPEH-CIUDSAMLSA-N Leu-Cys-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N GZAUZBUKDXYPEH-CIUDSAMLSA-N 0.000 description 3
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 3
- YWYQSLOTVIRCFE-SRVKXCTJSA-N Leu-His-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O YWYQSLOTVIRCFE-SRVKXCTJSA-N 0.000 description 3
- XWEVVRRSIOBJOO-SRVKXCTJSA-N Leu-Pro-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O XWEVVRRSIOBJOO-SRVKXCTJSA-N 0.000 description 3
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 3
- AKVBOOKXVAMKSS-GUBZILKMSA-N Leu-Ser-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O AKVBOOKXVAMKSS-GUBZILKMSA-N 0.000 description 3
- JIHDFWWRYHSAQB-GUBZILKMSA-N Leu-Ser-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JIHDFWWRYHSAQB-GUBZILKMSA-N 0.000 description 3
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 3
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 3
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 3
- MPGHETGWWWUHPY-CIUDSAMLSA-N Lys-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN MPGHETGWWWUHPY-CIUDSAMLSA-N 0.000 description 3
- VHXMZJGOKIMETG-CQDKDKBSSA-N Lys-Ala-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCCCN)N VHXMZJGOKIMETG-CQDKDKBSSA-N 0.000 description 3
- HWMZUBUEOYAQSC-DCAQKATOSA-N Lys-Gln-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O HWMZUBUEOYAQSC-DCAQKATOSA-N 0.000 description 3
- KZOHPCYVORJBLG-AVGNSLFASA-N Lys-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N KZOHPCYVORJBLG-AVGNSLFASA-N 0.000 description 3
- VMTYLUGCXIEDMV-QWRGUYRKSA-N Lys-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN VMTYLUGCXIEDMV-QWRGUYRKSA-N 0.000 description 3
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 3
- PPNCMJARTHYNEC-MEYUZBJRSA-N Lys-Tyr-Thr Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 PPNCMJARTHYNEC-MEYUZBJRSA-N 0.000 description 3
- YRAWWKUTNBILNT-FXQIFTODSA-N Met-Ala-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YRAWWKUTNBILNT-FXQIFTODSA-N 0.000 description 3
- QRHWTCJBCLGYRB-FXQIFTODSA-N Met-Ala-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O QRHWTCJBCLGYRB-FXQIFTODSA-N 0.000 description 3
- BQVJARUIXRXDKN-DCAQKATOSA-N Met-Asn-His Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 BQVJARUIXRXDKN-DCAQKATOSA-N 0.000 description 3
- XMMWDTUFTZMQFD-GMOBBJLQSA-N Met-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC XMMWDTUFTZMQFD-GMOBBJLQSA-N 0.000 description 3
- XBYKTPZCWQQSGB-IHRRRGAJSA-N Met-Cys-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XBYKTPZCWQQSGB-IHRRRGAJSA-N 0.000 description 3
- NCVJJAJVWILAGI-SRVKXCTJSA-N Met-Gln-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N NCVJJAJVWILAGI-SRVKXCTJSA-N 0.000 description 3
- KMSMNUFBNCHMII-IHRRRGAJSA-N Met-Leu-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN KMSMNUFBNCHMII-IHRRRGAJSA-N 0.000 description 3
- AWGBEIYZPAXXSX-RWMBFGLXSA-N Met-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N AWGBEIYZPAXXSX-RWMBFGLXSA-N 0.000 description 3
- WTHGNAAQXISJHP-AVGNSLFASA-N Met-Lys-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O WTHGNAAQXISJHP-AVGNSLFASA-N 0.000 description 3
- QTMIXEQWGNIPBL-JYJNAYRXSA-N Met-Met-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N QTMIXEQWGNIPBL-JYJNAYRXSA-N 0.000 description 3
- KYJHWKAMFISDJE-RCWTZXSCSA-N Met-Thr-Met Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCSC KYJHWKAMFISDJE-RCWTZXSCSA-N 0.000 description 3
- LPNWWHBFXPNHJG-AVGNSLFASA-N Met-Val-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN LPNWWHBFXPNHJG-AVGNSLFASA-N 0.000 description 3
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 3
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 3
- AJOKKVTWEMXZHC-DRZSPHRISA-N Phe-Ala-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 AJOKKVTWEMXZHC-DRZSPHRISA-N 0.000 description 3
- AYPMIIKUMNADSU-IHRRRGAJSA-N Phe-Arg-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O AYPMIIKUMNADSU-IHRRRGAJSA-N 0.000 description 3
- ZUQACJLOHYRVPJ-DKIMLUQUSA-N Phe-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 ZUQACJLOHYRVPJ-DKIMLUQUSA-N 0.000 description 3
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 description 3
- YXHYJEPDKSYPSQ-AVGNSLFASA-N Pro-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 YXHYJEPDKSYPSQ-AVGNSLFASA-N 0.000 description 3
- WFIVLLFYUZZWOD-RHYQMDGZSA-N Pro-Lys-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WFIVLLFYUZZWOD-RHYQMDGZSA-N 0.000 description 3
- JIWJRKNYLSHONY-KKUMJFAQSA-N Pro-Phe-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JIWJRKNYLSHONY-KKUMJFAQSA-N 0.000 description 3
- SPLBRAKYXGOFSO-UNQGMJICSA-N Pro-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2)O SPLBRAKYXGOFSO-UNQGMJICSA-N 0.000 description 3
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 description 3
- KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 description 3
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 3
- KIDXAAQVMNLJFQ-KZVJFYERSA-N Pro-Thr-Ala Chemical compound C[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](C)C(O)=O KIDXAAQVMNLJFQ-KZVJFYERSA-N 0.000 description 3
- FIODMZKLZFLYQP-GUBZILKMSA-N Pro-Val-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FIODMZKLZFLYQP-GUBZILKMSA-N 0.000 description 3
- IDQFQFVEWMWRQQ-DLOVCJGASA-N Ser-Ala-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O IDQFQFVEWMWRQQ-DLOVCJGASA-N 0.000 description 3
- RZUOXAKGNHXZTB-GUBZILKMSA-N Ser-Arg-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O RZUOXAKGNHXZTB-GUBZILKMSA-N 0.000 description 3
- CRZRTKAVUUGKEQ-ACZMJKKPSA-N Ser-Gln-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O CRZRTKAVUUGKEQ-ACZMJKKPSA-N 0.000 description 3
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 3
- AXOHAHIUJHCLQR-IHRRRGAJSA-N Ser-Met-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CO)N AXOHAHIUJHCLQR-IHRRRGAJSA-N 0.000 description 3
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 3
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 3
- PURRNJBBXDDWLX-ZDLURKLDSA-N Ser-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CO)N)O PURRNJBBXDDWLX-ZDLURKLDSA-N 0.000 description 3
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 3
- JMZKMSTYXHFYAK-VEVYYDQMSA-N Thr-Arg-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O JMZKMSTYXHFYAK-VEVYYDQMSA-N 0.000 description 3
- CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 description 3
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 3
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 3
- NYQIZWROIMIQSL-VEVYYDQMSA-N Thr-Pro-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O NYQIZWROIMIQSL-VEVYYDQMSA-N 0.000 description 3
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 3
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 3
- TZQWJCGVCIJDMU-HEIBUPTGSA-N Thr-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)O)N)O TZQWJCGVCIJDMU-HEIBUPTGSA-N 0.000 description 3
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 3
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 3
- HVPPEXXUDXAPOM-MGHWNKPDSA-N Tyr-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HVPPEXXUDXAPOM-MGHWNKPDSA-N 0.000 description 3
- HZWPGKAKGYJWCI-ULQDDVLXSA-N Tyr-Val-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(C)C)C(O)=O HZWPGKAKGYJWCI-ULQDDVLXSA-N 0.000 description 3
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 3
- UUYCNAXCCDNULB-QXEWZRGKSA-N Val-Arg-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O UUYCNAXCCDNULB-QXEWZRGKSA-N 0.000 description 3
- HNWQUBBOBKSFQV-AVGNSLFASA-N Val-Arg-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HNWQUBBOBKSFQV-AVGNSLFASA-N 0.000 description 3
- HIZMLPKDJAXDRG-FXQIFTODSA-N Val-Cys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N HIZMLPKDJAXDRG-FXQIFTODSA-N 0.000 description 3
- NYTKXWLZSNRILS-IFFSRLJSSA-N Val-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N)O NYTKXWLZSNRILS-IFFSRLJSSA-N 0.000 description 3
- RHYOAUJXSRWVJT-GVXVVHGQSA-N Val-His-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RHYOAUJXSRWVJT-GVXVVHGQSA-N 0.000 description 3
- DJQIUOKSNRBTSV-CYDGBPFRSA-N Val-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)C)N DJQIUOKSNRBTSV-CYDGBPFRSA-N 0.000 description 3
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 3
- JAKHAONCJJZVHT-DCAQKATOSA-N Val-Lys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N JAKHAONCJJZVHT-DCAQKATOSA-N 0.000 description 3
- XBJKAZATRJBDCU-GUBZILKMSA-N Val-Pro-Ala Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O XBJKAZATRJBDCU-GUBZILKMSA-N 0.000 description 3
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 3
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 3
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 3
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 3
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 3
- 108010005233 alanylglutamic acid Proteins 0.000 description 3
- 108010093581 aspartyl-proline Proteins 0.000 description 3
- 108010038633 aspartylglutamate Proteins 0.000 description 3
- 108010047857 aspartylglycine Proteins 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 108010060199 cysteinylproline Proteins 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 108010075431 glycyl-alanyl-phenylalanine Proteins 0.000 description 3
- 108010084264 glycyl-glycyl-cysteine Proteins 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 108010010147 glycylglutamine Proteins 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 108010015792 glycyllysine Proteins 0.000 description 3
- 108010037850 glycylvaline Proteins 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 108010078274 isoleucylvaline Proteins 0.000 description 3
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 3
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 3
- 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 description 3
- 108010064235 lysylglycine Proteins 0.000 description 3
- 108010054155 lysyllysine Proteins 0.000 description 3
- 108010038320 lysylphenylalanine Proteins 0.000 description 3
- 108010085203 methionylmethionine Proteins 0.000 description 3
- 108010068488 methionylphenylalanine Proteins 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 108010048818 seryl-histidine Proteins 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 3
- 108010073969 valyllysine Proteins 0.000 description 3
- OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 2
- ISCYZXFOCXWUJU-KZVJFYERSA-N Ala-Thr-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O ISCYZXFOCXWUJU-KZVJFYERSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- FGGKGJHCVMYGCD-UKJIMTQDSA-N Glu-Val-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGGKGJHCVMYGCD-UKJIMTQDSA-N 0.000 description 2
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- BRJGUPWVFXKBQI-XUXIUFHCSA-N Pro-Leu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRJGUPWVFXKBQI-XUXIUFHCSA-N 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- WFAUDCSNCWJJAA-KXNHARMFSA-N Thr-Lys-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(O)=O WFAUDCSNCWJJAA-KXNHARMFSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101150007350 CEF gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 206010058854 Cytomegalovirus viraemia Diseases 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 101100395310 Homo sapiens HLA-A gene Proteins 0.000 description 1
- HXIDVIFHRYRXLZ-NAKRPEOUSA-N Ile-Ser-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O)N HXIDVIFHRYRXLZ-NAKRPEOUSA-N 0.000 description 1
- QGXQHJQPAPMACW-PPCPHDFISA-N Ile-Thr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QGXQHJQPAPMACW-PPCPHDFISA-N 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- MSIYNSBKKVMGFO-BHNWBGBOSA-N Thr-Gly-Pro Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N)O MSIYNSBKKVMGFO-BHNWBGBOSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
この出願は、図面を含むその全体が参照により本明細書に組み込まれる、2018年5月11日に出願された米国仮出願第62/670,656号の優先権を主張する。
本発明は、国立衛生研究所(NIH)の国立癌研究所によって授与された助成金番号CA075444の下で政府の支援を受けてなされた。政府は本発明において一定の権利を有する。
改変ワクシニアアンカラ(MVA)は、ほとんどの哺乳動物細胞において増殖しない、遺伝子操作された、高度に弱毒化されたワクシニアウイルス株である。哺乳類細胞で増殖するMVAの能力は後期のウイルス集合でブロックされるため、この特性はウイルス又は外来遺伝子の発現に最小限の影響を与える。ただし、DNAは複製を続け、したがってRNA生合成の効率的なテンプレートとして機能し、高レベルのタンパク質合成をもたらす。MVAはまた、大きな外来遺伝子容量と複数の統合サイト
ワクチン抗原を発現するための望ましいベクターにする2つの特徴を持つ。MVAは、異種タンパク質の生産に関して確立された安全記録と多様性を持つ。実際、感染症と癌の治療のためのMVAベースのワクチンが開発され、フェーズI/IIの臨床試験に到達した。
一態様では、本開示は、2つ以上のサイトメガロウイルス(CMV)抗原、例えば、ヒトCMV抗原、を共発現するための発現系に関する。発現系は、2つ以上のCMV抗原又はその抗原性部分をコードする2つ以上の核酸配列が挿入された遺伝子組換え改変ワクシニアアンカラ(rMVA)ベクターを包含する。いくつかの実施形態において、CMV抗原又はその抗原性フラグメントは、IE1エクソン4(IE1/e4)、IE2エクソン5(IE2/e5)、IEfusion(例えば、IE1/e4及びIE2/e5の融合)、及びpp65を包含する。様々な実施形態において、pp65は、IE1/e4、IE2/e5、又はIEfusionと共発現され得る。発現系は、単一のベクターから同時にCMV抗原を共発現させることができる。いくつかの実施形態において、2つ以上のCMV抗原をコードする核酸配列は、044L/045L、IGR3、G1L/I8R、及びDel3を包含する1つ以上の挿入部位に挿入される。追加の挿入部位には、表1にリストされている部位が含まれる。
(1)CMV抗原又はその抗原性断片をコードする1つ又は複数の核酸配列を、044L/045L、IGR3、G1L/I8R、及びDel3を包含する1つ又は複数の挿入部位に、並びにDel2を包含しない、表1にリストされている追加の挿入部位に挿入すること;
(2)連続するシトシン又はグアニンを除去することにより、CMV抗原をコードする核酸配列を最適化するコドン;及び
(3)CMV抗原のアミノ酸配列に1つ又は複数の変異を導入すること;
のうちの1つ以上を組み込むことによって、2つ以上のCMV抗原又はその抗原性フラグメントを発現するrMVAの継代(passage)時の安定性を改善する方法に関する。いくつかの実施形態では、CMV抗原又はその抗原性フラグメントには、IE1エクソン4(IE1/e4)、IE2エクソン5(IE2/e5)、IEfusion(例えば、IE1とIE2又はIE1/e4とIE2/e5の融合)、及びpp65が含まれる。
現在のトリプレックスワクチン製剤は、3つの免疫優勢タンパク質: pp65及び前初期タンパク質IE1及びIE2の融合、を包含するが、限定的な製造特性を有する。:
1)IEfusion挿入の安定性を維持するために限定された継代を受けなければならない;
2)IEfusionの不安定性なしにウイルス増殖を可能にするための制限された増殖条件;
3)大規模な臨床ロットの大量生産の場合、現在のTriplex製剤(formulation)は、最も効率的で長期的な生産戦略ではない。
1)遺伝子の安定性にとって好ましい環境となる可能性のあるMVAでの複数のユニークな遺伝子挿入部位の使用;
2)コドン「ゆらぎ」位置での突然変異を含むことが以前に同定された遺伝子配列内のDNA突然変異「ホットスポット」の除去、それにより連続するC又はGヌクレオチドを破壊する;及び
3)タンパク質発現の増加のためのポックスウイルスコドン最適化。
いくつかの実施形態では、IEfusionは、MVA内の他の部位に挿入される。候補サイトには、Del3[5、6]、G1L/I8R[7、8]、IGR3[9]、及び044L/045L[10]が含まれる。追加の挿入部位を表1に列挙する。いくつかの実施形態では、挿入部位はDel2を包含しない。いくつかの実施形態において、遺伝子配列中の3つ以上、4つ以上、5つ以上、6つ以上の連続したC又はGヌクレオチドは、同一のアミノ酸同一性を維持するゆらぎ塩基置換によって破壊される。
1)IEfusionをIE1及びIE2遺伝子コンポーネントに分割すること;
2)3つの遺伝子すべてをMVAの別々の挿入部位に挿入すること、及びインサートの変異遺伝子配列を使用すること;
3)MVAの新しい挿入サイトを探索する。
挿入部位のいくつかの例を表1に示す。
データベース検索: タンデム質量スペクトル(MS/MS)は、ゲル内トリプシン消化及びその後のペプチド抽出を介して、勾配4〜20%SOS−PAGEゲル(Bio−Rad、USA)から抽出された。電荷状態のデコンボリューションとデアイソトーピングは実行されなかった。すべてのMS/MSサンプルは、Sequest(XCorrのみ)を使用して分析した(Thermo Fisher Scientific、米国カリフォルニア州サンノゼ、Proteome Discoverer 2.1.0.81のバージョンlseNode)。Sequest(XCorrのみ)は、crap_ncbi.fasta; Heidi_20170828.fasta; human_refseq.fastaを検索するように設定された(不明なバージョン、73204エントリ)。消化酵素が非特異的であると仮定する。
(不明なバージョン、73204エントリ)は、消化酵素が非特異的であると想定しています。 Sequest(XCorrのみ)は、0.60Daのフラグメントイオン質量許容値と0.60Daの親イオン許容値で検索されました。Sequest(XCorrのみ)は、0.60Daのフラグメントイオン質量許容値と0.60Daの10.0PPMの親イオン許容値で検索された。システインのカルバミドメチルは、固定修飾としてSequest(XCorrのみ)で指定された。アスパラギンの脱アミド化、メチオニンの酸化、及びN末端のアセチルは、Sequest(XCorrのみ)で可変修飾として指定されている。
この研究において、「安定性」は、完全長の遺伝子が存在し、完全長のタンパク質が存在することを確認するために、ポリメラーゼ連鎖反応(PCR)、DNAシーケンス、及びウエスタンブロットを介して監視されているMVA内の目的の遺伝子の完全性によって評価された。Triplexの元の設計には、連続継代時に不安定性を引き起こし、タンパク質発現を大幅に低下させるpSynプロモーターが含まれていた。pSynプロモーターは以前に改変ワクシニアウイルスH5(mH5)プロモーターに置き換えられており(図2A)、免疫原性を維持しながらIEfusionタンパク質の安定性の増加が観察された[1、2]。発現の安定性をさらに改善するために、発がんに関連する可能性のある遺伝子活性化イベントを防ぎ、可能な転写ユニットの数を減らすために、エクソン2/エクソン3内にコードされた核局在化配列と転写活性化ドメイン、及びHCMVAD169からのIE1とIE2の重複するリーディングフレームは省略された。(図2A)[3]。したがって、ヌクレオチドやアミノ酸を追加せずに、間にシームレスな接合部を持つIE1/IE2融合体を、修飾ワクシニアアンカラ(MVA)のDel2部位に挿入し、非修飾リンタンパク質pp65[4]をMVAのDel3部位に挿入した[1]。これらの変更後、IEfusionの安定性は、タンパク質(図2B)又はDNAレベル(図2C)のいずれでもないものの、CEFの10ウイルス継代にわたってRNAレベルで観察された[1]。増殖のために、IEfusionサンプルは評価の前に約5継代を受けた。したがって、図2Bでは、P1とマークされたサンプルは、CEFで分析する前に5回継代された可能性がある。一方、図2Bで使用されている臨床Triplexは、それほど多くの継代を受けていない;したがって、IEfusionのP1では安定性の低下がすでに観察されている(図2B及び2C)。
本明細書に開示される第1世代トリプレックス及び新しいトリプレックスコンストラクトのゲノム構造は類似しているが、MVAの他の部位に挿入されたIEfusion(図1に示すスキームI)は、自然突然変異のホットスポットを減らしたり、ポックスウイルスのコドン最適化を介して発現を増やしたりするためのIEfusionへの遺伝子改変の調査に加えて評価された(すなわち、ゆらぎ位置(4 nt)及びワクシニアウイルス発現(VacO)の最適化)。第1世代のTriplexには、野生型MVAへのIEfusionの相同組換えを促進するトランスファープラスミドを介して生成されたHCMV AD169DNA配列を使用したMVAのDel2のIEfusionとDel3のpp65が含まれている[3]。図2を参照。このプロセスには時間がかかる可能性があるため、バクテリア人工染色体(BAC)技術が利用された。BACテクノロジー[11、12]及びアンパッサン突然変異誘発[13、14]を適用して、pp65及びIEfusionのさまざまな反復を発現する新しいMVAコンストラクトを生成することにより、提案されたウイルスコンストラクトの各々(表2)が迅速に生成され、テストされた。
突然変異のホットスポットは、連続するC又はGヌクレオチド塩基の、続いて、IEfusionのDNA配列を最適化するワクシニアウイルスコドン(VacOとして指定される)の実行を破壊することによって除去された[15]。「X」でマークされた表2に示されるコンストラクトは、PCR及びウエスタンブロットによって安定性について分析され、その挿入部位内の遺伝子の完全性及び継代後の発現をモニターした。このタイプの分析は、DNA又はタンパク質レベルでの不安定性に関する洞察を提供する。
目標は、ワクチンウイルスの大規模増殖のために、最低10継代で3つすべての抗原を安定して発現するMVAを生成するため、挿入部位と遺伝子修飾の最も安定した組み合わせを見つけることであった。IE1、IE2、及びpp65の安定した発現を可能にする挿入部位の最も安定した組み合わせを見つけるために、3つの主要なポイントを考慮して新しいワクチン構築戦略が開始された:
1)IEfusionをそのIE1/IE2コンポーネントに分割すること;
2)3つすべての遺伝子の変異遺伝子配列をMVAの別々の挿入部位に挿入すること;及び
3)MVAの新しい挿入サイトを探索する。
ヌクレオチド修飾後の融合タンパク質としてのIE1及びIE2の安定性を高めることに限られた成功しかなかったので、IE1とIE2を分離し、且つ各遺伝子を別々の挿入部位に挿入した後、新しいサイトのそれぞれにおける各遺伝子の安定性を分析した。元のIEfusionコンストラクトはIE1とIE2を分割するためのテンプレートとして使用され、各コンポーネントは別々のmH5プロモーターの制御下にあった[1]。表2は、10継代以上(≧10)にわたってIE1及びIE2を安定して発現するMVAを生じさせるために生成されたすべてのコンストラクトを示す。さらに、連続するC及びGヌクレオチドの除去などの他の変更、並びにIEfusionで行われたような遺伝子のコドン最適化が組み込まれた。IE1及びIE2遺伝子の異なる配列修飾を、CEFの安定性について分析し、また、BACテクノロジーを使用してさまざまなMVAコンストラクトを生成した。Del2の不安定性が観察されたため[15]、Del2サイトは候補サイトとしてさらに追求されなかった。
IE2を発現するMVAコンストラクトはいずれも完全長のIE2タンパク質を産生しなかったが、1つのコンストラクトであるMVA::IE2(044L/045L)(表2)は、10回のウイルス継代すべてでIE2関連産物を発現した(図7)。〜20kDa及び〜40kDaのフラグメントをもたらすIE2の代替タンパク質産物は、IE2について以前に記載されている[17−19]。これらの代替タンパク質産物の同一性を決定するために、ゲル内トリプシン消化、続いてLC−MS/MSを実施した。質量分析データ分析により、約20kDaの生成物は主にIE2のC末端部分(48%の被覆率)であるのに対し、約40kDaの生成物は主にN末端(34%の被覆率)であることが明らかになった(表4)。全長IE2は、コントロールとして分析に含まれた(材料と方法で説明されているように実行されたタンパク質確率計算)。
IE1にはヌクレオチドレベルの特性があり、一部の場所で不安定になる;IE1をMVAの別のサイトに挿入すると、不安定さが軽減された。IE2の不安定性は、この方法だけでは解決できまなかった。推定上のIE2機能ドメインが報告されている[20]。IE2のC末端は、DNA結合、トランス活性化、及び自己抑制に重要な「コア」ドメインの一部として説明されている(図8A)。コアドメインに隣接する領域には、IE2タンパク質とDNAの相互作用に影響を与えることなく変異させることができるZnフィンガー結合ドメインが含まれている。コアドメインに隣接する領域は、「特異的かつ必須のモジュレーター」ドメイン(SEM)と名付けられた(図8A)。SEM領域内の変異は、以前IE2に関連付けられていたすべての機能を損なわなかったが、この領域内の異なるシーケンス要件が異なるIE2機能に影響を与えることが観察されている。IE2のC末端内の2つのHis残基は、推定されるZnフィンガー結合ドメイン(図8A)、His446及びHis452内で同定された[21、22]。これらのIE2残基を変異させても、DNA結合能力が失われることはなく、HCMV内又はアデノウイルスなどの異種システムでのIE2発現が妨げられることもない[23]。最後の37アミノ酸残基を変異させた結果、IE2の自己抑制及びトランス活性化機能に必要であると判断された[24−27]。2つのヒスチジン(H)残基は、部位特異的変異誘発を使用してアラニン(A)に変異したが、SEMドメイン又はコアドメインのいずれからも他のC末端残基は変化しなかった。この決定は、C末端の最後の約37アミノ酸残基がIE2活性にとって重要である場合、これらの残基が免疫原性エピトープをコードしている可能性があるという考えによるものであった。SEM内の変異残基は、IE2活性に影響を与えることなく、十分に許容される[20];したがって、この領域内の変更が、CEFでのウイルス継代時にIE2遺伝子及びMVAでのそのタンパク質産物の遺伝的及びタンパク質安定性に役立つかどうかをさらに調査した。
IE1とpp65の両方を安定して発現する2つのコンストラクトが同定された: (A)MVA BAC::IE1 4nt(IGR3)::pp65(Del3)及び(B)MVA BAC::IE1 VacO(IGR3)::pp65(Del3)。IE2の安定性に対するH363A及び/又はH369Aの変異の影響を評価したら、前述のいずれかのコンストラクトのMVAサイト044L/045Lにさまざまな変異IE2バージョンを挿入した。IE2の安定性を評価した以前の研究に基づいて、IE1はヌクレオチドレベルでいくつかの場所で不安定になる特性を持っているが、MVAの別のサイトにIE1を挿入することで不安定性が軽減されることが明らかになった。対照的に、IE2は、MVAでの発現を「安定」させる場所と配列を見つけるのが困難であった。C末端Hisの変異により、044L/045L部位内の遺伝子とタンパク質の安定性が改善された。IE2が不安定性の主な原因であると特定し、IEfusionを再評価した。IE2部分のC末端にあるHis残基の変異誘発を包含する、IEfusionの変異体が生成された。しかし、Del2に挿入された遺伝子は不安定であるため、その部位に遺伝子を挿入することはできなかった。IEfusion、IEfusion 4nt、及びIEfusion VacOのH363A及び/又はH369A変異体のいずれかが生成された。IEfusionのこれらのバリアントは、IGR3又は044L/045Lのいずれかに挿入され、Del3にはpp65も含まれている。Triplexバリアントが完成したら、トランスジェニックHLA発現マウスのワクチン接種は、IEfusion変異体によって生成された免疫原性と、分離されたIE1及びIE2遺伝子を持つ再誘導トリプレックスを比較するために使用できる。これらはすべて、図8に示すようにHis変異を伴う。
新しいトリプレックスバリアントが完全に構築されると、免疫原性研究は、IEfusionバリアント変異体及び再誘導された第2世代トリプレックスによって生成された免疫原性を、第1世代トリプレックスと比較して分離されたIE1及びIE2バリアントと比較するために行われた。HLA−B HLA−B*0702(B7)又はHLA−A*0201(HHD−II)クラスI分子を発現するトランスジェニックC56BL/6マウスを、トリプレックスに加えて6つの第2世代トリプレックスコンストラクト(A(i)、A(v)、B(i)、B(iii)、B(vii)、IEfusion 4nt H363A(IGR3)::pp65(Del3))で免疫した。マウスに、2.5×107PFU(B7マウスの場合)又は5×107PFU(HHD−IIの場合)のいずれかを用いた腹腔内(i.p.)経路により、さまざまなコンストラクトを3週間間隔で2回ワクチン接種した後、脾細胞を単離した。第2世代トリプレックスによって誘発されたヒトMHC制限T細胞応答を、ELISpotによって評価された元のトリプレックス及びワクチン未接種のナイーブグループと比較した(表6)。表6では、HLA−B*0702(B7、上部)又はHLA−A*0201(HHD−II、下部)クラスI分子を発現するトランスジェニックC57BL/6マウスを、IEfusion/pp65(IEFus)又はIE1/IE2/pp65のいずれかを発現するさまざまなコンストラクトで免疫した。抗原特異的T細胞応答は、pp65、IE1、及びIE2特異的ライブラリー、pp65及びIE1のHLA−B*0702又はHLAA*0201制限免疫優勢エピトープを使用したIFN−γ酵素結合免疫吸収スポット(ELISpot)アッセイによって決定された。DMSOをネガティブコントロールとして使用した。平均値と平均値の標準誤差(SEM)値は、HLA−B7(上部)又はHHD−II(下部)マウスの(N)数から計算された。SFC: サイトカイン特異的スポット形成細胞。
MVAで発現されるIE2の安定性の増加は、IE2タンパク質のC末端内に存在する1つ又は2つのHis残基の突然変異の際に観察された。IE2変異体がIE2全体の安定性に及ぼす影響を調べるために、MVAは、IE2の2つのコピーを収容するように構築された: G1LのIE2 NCO(野生型)と、IE2変異体を収容する044/045Lサイトのもう一方。IE2の2つのコピーを含むMVAコンストラクトは、ベビーハムスター腎臓(BHK)細胞のP5に継代された(図28)。IE2の両方のコピーのPCR分析は、非特異的なPCR産物を示さず、正しいサイズの産物のみを示している(図28A)。一方、ウエスタンブロット分析では、2つのIE2コピーを含むコンストラクトでIE2の一貫した発現が示されるが、MVA:IE2 NCO(G1L)では、完全長のIE2発現が減少し、約40kDaのバンドが出現し(図28B)、以前に観察された切り捨てられた(truncated)産物を示している(図7)。2つのIE2コピーを持つMVAからのIE2の発現を示すウエスタンブロットにはいくつかの分解産物があったが、MVA:IE2 NCO(G1L)で観察されたIE2の継代及び分解から蓄積すると予想される分解産物の同時増加はなかった。これらの結果は、変異型IE2遺伝子インサートの存在の結果として以前に観察されたIE2不安定性の「救済」を示唆している可能性がある。
SEQUENCE LISTING
<110>
CITY OF HOPE
<120>
GENETICALLY MODIFIED RECOMBINANT VACCINIA ANKARA (RMVA) VACCINES
OF IMPROVED STABILITY AND METHODS OF PREPARATION THEREOF
<130>
054435-8183.WO00
<140>
PCT/US2019/031866
<141>
2019-05-10
<150>
62/670,656
<151>
2018-05-11
<160>
29
<170>
PatentIn version 3.5
<210>
1
<211>
2709
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IEfusion-VacO DNA sequence
<400>
1
atggtgaagc
aaatcaaggt cagagtggac atggtaagac acagaattaa
ggaacacatg 60
ttgaagaagt
atactcaaac agaggagaag ttcaccggtg ccttcaatat
gatgggtgga 120
tgtctacaga
acgctttgga tatcttagat aaggtacatg aaccattcga
agaaatgaag 180
tgcattggat
tgacaatgca atcaatgtat gagaactaca tagtgccaga
ggataagcgt 240
gaaatgtgga
tggcatgcat caaggagtta catgatgtat ccaaaggagc
agccaacaag 300
ctaggtggtg
ctttgcaagc gaaggcaaga gcgaagaagg atgaattgag
acgaaagatg 360
atgtacatgt
gctatcgaaa catcgaattc ttcactaaga actcagcgtt
tcctaagact 420
accaatggat
gcagtcaagc tatggctgcg cttcagaact tgcctcaatg tagtcctgat
480
gaaatcatgg
catatgcaca gaagatcttc aagatcttag atgaggaaag
agacaaggta 540
ttgactcata
tcgatcacat attcatggat atactaacaa catgtgtaga
aacgatgtgt 600
aacgagtaca
aggtaacttc ggacgcttgt atgatgacta tgtacggagg
aatatctcta 660
cttagtgagt
tctgtcgagt tctatgctgt tacgtattag aagaaactag
tgtaatgtta 720
gcgaagagac
cattgatcac taagcctgaa gtgatctcgg ttatgaagag
acgaatagag 780
gagatctgta
tgaaggtgtt cgcacaatac atcttaggag ctgatcctct
aagagtgtgt 840
agtccatcgg
tagacgattt gagagctata gcggaggaat ctgacgagga
agaggcaata 900
gttgcataca
cacttgctac agctggagta tccagttctg attctcttgt
aagtcctccg 960
gagtcacctg
tgccagcaac cataccgttg agtagtgtga ttgtggctga gaactcggat
1020
caggaagagt
ctgagcaatc cgatgaagaa gaggaggaag gagcacaaga ggagagagaa 1080
gatactgtct
ctgtgaagag tgaacctgta tctgaaatcg aggaagtagc acctgaggaa
1140
gaggaggatg
gagccgaaga accaacagct tcgggtggta agtcaactca tccgatggta
1200
accagatcta
aggcagacca gggagacatc ctagcacaag cagtgaacca tgctggaatt
1260
gactcatctt
cgaccggacc aactctaacg actcattcat gttcggttag ttctgctcct
1320
cttaacaagc
ctacacctac ctcggtagct gttaccaaca cacctttacc aggagcatca
1380
gcaacacctg
agttgtctcc aagaaagaag cctcgtaaga ccacgagacc gttcaaggtg
1440
atcatcaagc
caccagtacc acctgctccg atcatgttgc cattgatcaa gcaggaggac
1500
attaagccag
aacctgactt cacgatacag taccgtaaca agatcataga tacagcagga
1560
tgcatagtga
tctcagatag tgaagaggag caaggtgagg aagtggagac tagaggagcc
1620
acagccagtt
cgccttccac aggatccgga actcctagag taactagtcc gacacatcca
1680
ctttcccaga
tgaatcatcc acctctaccg gatcctctag gacgaccaga tgaagattct
1740
tcttcatcta
gttcaagttc ttgctcatcc gcgagtgata gtgagtcaga aagtgaagag
1800
atgaagtgct
cttctggtgg tggagctagt gtcacttcat ctcatcatgg acgaggagga
1860
tttggaggtg
ctgcgagtag ttccttacta agttgtggac atcagtcatc tggtggtgca
1920
tctactggac
ctagaaagaa gaagtcaaag agaatctccg aattggataa tgagaaagtg
1980
agaaacatca
tgaaggacaa gaacacgccg ttctgcactc cgaatgttca gacgagaaga
2040
ggacgagtga
agatagatga agtatcacga atgttcagaa acacaaatcg ttctctagag
2100
tacaagaatc
ttccgttcac cataccttcg atgcaccaag tattagatga ggctatcaag
2160
gcatgtaaga
ccatgcaagt taacaacaaa ggaatacaga tcatctacac tagaaaccat
2220
gaggttaaga
gtgaggtgga tgccgtacgt tgtagattgg gaacgatgtg taaccttgcg
2280
ctatctactc
ctttcctaat ggagcatact atgcctgtga ctcatcctcc tgaagtggct
2340
caaagaacag
ctgatgcttg taacgaaggt gtgaaagctg cttggtccct aaaggagtta
2400
catacacacc
aactttgtcc acgatccagt gactacagaa acatgatcat tcatgcagct
2460
acgcctgtag
atctacttgg agctcttaac ctatgtcttc ctttgatgca gaagttccct
2520
aagcaagtga
tggtgagaat cttctcgacg aatcaaggag gattcatgtt accgatatac
2580
gagacagctg
caaaggctta cgctgtcggt cagttcgagc aaccgactga aacgcctcct
2640
gaggacttag
atacattgtc tttggcgata gaagcagcga ttcaggatct tagaaacaag
2700
agtcagtaa
2709
<210>
2
<211>
2709
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IEfusion DNA sequence
<400>
2
atggtcaaac
agattaaggt tcgagtggac atggtgcggc atagaatcaa
ggagcacatg 60
ctgaaaaaat
atacccagac ggaagagaaa ttcactggcg cctttaatat
gatgggagga 120
tgtttgcaga
atgccttaga tatcttagat aaggttcatg agcctttcga
ggagatgaag 180
tgtattgggc
taactatgca gagcatgtat gagaactaca ttgtacctga
ggataagcgg 240
gagatgtgga
tggcttgtat taaggagctg catgatgtga gcaagggcgc
cgctaacaag 300
ttggggggtg
cactgcaggc taaggcccgt gctaaaaagg atgaacttag
gagaaagatg 360
atgtatatgt
gctacaggaa tatagagttc tttaccaaga actcagcctt ccctaagacc
420
accaatggct
gcagtcaggc catggcggca ctgcagaact tgcctcagtg
ctcccctgat 480
gagattatgg
cttatgccca gaaaatattt aagattttgg atgaggagag
agacaaggtg 540
ctcacgcaca
ttgatcacat atttatggat atcctcacta catgtgtgga
aacaatgtgt 600
aatgagtaca
aggtcactag tgacgcttgt atgatgacca tgtacggggg
catctctctc 660
ttaagtgagt
tctgtcgggt gctgtgctgc tatgtcttag aggagactag
tgtgatgctg 720
gccaagcggc
ctctgataac caagcctgag gttatcagtg taatgaagcg
ccgcattgag 780
gagatctgca
tgaaggtctt tgcccagtac attctggggg ccgatcctct
gagagtctgc 840
tctcctagtg
tggatgacct acgggccatc gccgaggagt cagatgagga
agaggctatt 900
gtagcctaca
ctttggccac cgctggtgtc agctcctctg attctctggt
gtcaccccca 960
gagtcccctg
tacccgcgac tatccctctg tcctcagtaa ttgtggctga gaacagtgat 1020
caggaagaaa
gtgagcagag tgatgaggaa gaggaggagg gtgctcagga ggagcgggag
1080
gacactgtgt
ctgtcaagtc tgagccagtg tctgagatag aggaagttgc cccagaggaa
1140
gaggaggatg
gtgctgagga acccaccgcc tctggaggca agagcaccca ccctatggtg
1200
actagaagca
aggctgacca gggtgacatc ctcgcccagg ctgtcaatca tgccggtatc
1260
gattccagta
gcaccggccc cacgctgaca acccactctt gcagcgttag cagcgcccct
1320
cttaacaagc
cgacccccac cagcgtcgcg gttactaaca ctcctctccc cggggcatcc
1380
gctactcccg
agctcagccc gcgtaagaaa ccgcgcaaaa ccacgcgtcc tttcaaggtg
1440
attattaaac
cgcccgtgcc tcccgcgcct atcatgctgc ccctcatcaa acaggaagac
1500
atcaagcccg
agcccgactt taccatccag taccgcaaca agattatcga taccgccggc
1560
tgtatcgtga
tctctgatag cgaggaagaa cagggtgaag aagtcgaaac ccgcggtgct
1620
accgcgtctt
ccccttccac cggcagcggc acgccgcgag tgacctctcc cacgcacccg
1680
ctctcccaga
tgaaccaccc tcctcttccc gatcccttgg gccggcccga tgaagatagt
1740
tcctcttcgt
cttcctcctc ctgcagttcg gcttcggact cggagagtga gtccgaggag
1800
atgaaatgca
gcagtggcgg aggagcatcc gtgacctcga gccaccatgg gcgcggcggt
1860
tttggtggcg
cggcctcctc ctctctgctg agctgcggcc atcagagcag cggcggggcg
1920
agcaccggac
cccgcaagaa gaagagcaaa cgcatctccg agttggacaa cgagaaggtg
1980
cgcaatatca
tgaaagataa gaacaccccc ttctgcacac ccaacgtgca gactcggcgg
2040
ggtcgcgtca
agattgacga ggtgagccgc atgttccgca acaccaatcg ctctcttgag
2100
tacaagaacc
tgcccttcac gattcccagt atgcaccagg tgttagatga ggccatcaaa
2160
gcctgcaaaa
ccatgcaggt gaacaacaag ggcatccaga ttatctacac ccgcaatcat
2220
gaggtgaaga
gtgaggtgga tgcggtgcgg tgtcgcctgg gcaccatgtg caacctggcc
2280
ctctccactc
ccttcctcat ggagcacacc atgcccgtga cacatccacc cgaagtggcg
2340
cagcgcacag
ccgatgcttg taacgaaggc gtcaaggccg cgtggagcct caaagaattg
2400
cacacccacc
aattatgccc ccgttcctcc gattaccgca acatgatcat ccacgctgcc
2460
acccccgtgg
acctgttggg cgctctcaac ctgtgcctgc ccctgatgca aaagtttccc
2520
aaacaggtca
tggtgcgcat cttctccacc aaccagggtg ggttcatgct gcctatctac
2580
gagacggccg
cgaaggccta cgccgtgggg cagtttgagc agcccaccga gacccctccc
2640
gaagacctgg
acaccctgag cctggccatc gaggcagcca tccaggacct gaggaacaag
2700
tctcagtaa
2709
<210>
3
<211>
2709
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IEfusion-4nt DNA sequence
<400>
3
atggtcaaac
agattaaggt tcgagtggac atggtgcggc atagaatcaa
ggagcacatg 60
ctgaagaagt
atacccagac ggaagagaaa ttcactggcg cctttaatat
gatgggagga 120
tgtttgcaga
atgccttaga tatcttagat aaggttcatg agcctttcga
ggagatgaag 180
tgtattgggc
taactatgca gagcatgtat gagaactaca ttgtacctga
ggataagcgg 240
gagatgtgga
tggcttgtat taaggagctg catgatgtga gcaagggcgc
cgctaacaag 300
ttaggaggtg
cactgcaggc taaggcccgt gctaagaagg atgaacttag
gagaaagatg 360
atgtatatgt
gctacaggaa tatagagttc tttaccaaga actcagcctt
ccctaagacc 420
accaatggct
gcagtcaggc catggcggca ctgcagaact tgcctcagtg
ctctcctgat 480
gagattatgg
cttatgccca gaagatattt aagatcttgg atgaggagag
agacaaggtg 540
ctcacgcaca
ttgatcacat atttatggat atcctcacta catgtgtgga
aacaatgtgt 600
aatgagtaca
aggtcactag tgacgcttgt atgatgacca tgtacggagg
catctctctc 660
ttaagtgagt
tctgtcgggt gctgtgctgc tatgtcttag aggagactag
tgtgatgctg 720
gccaagcggc
ctctgataac caagcctgag gttatcagtg taatgaagcg
ccgcattgag 780
gagatctgca
tgaaggtctt tgcccagtac attctaggtg ccgatcctct
gagagtctgc 840
tctcctagtg
tggatgacct acgggccatc gccgaggagt cagatgagga
agaggctatt 900
gtagcctaca
ctttggccac cgctggtgtc agctcctctg attctctggt gtcacctcca
960
gagtcacctg
tacccgcgac tatccctctg tcctcagtaa ttgtggctga gaacagtgat
1020
caggaagaaa
gtgagcagag tgatgaggaa gaggaggagg gtgctcagga ggagcgggag
1080
gacactgtgt
ctgtcaagtc tgagccagtg tctgagatag aggaagttgc tccagaggaa
1140
gaggaggatg
gtgctgagga acccaccgcc tctggaggca agagcaccca ccctatggtg
1200
actagaagca
aggctgacca gggtgacatc ctcgcccagg ctgtcaatca tgccggtatc
1260
gattccagta
gcaccggacc tacgctgaca acccactctt gcagcgttag cagcgctcct
1320
cttaacaagc
cgactccaac cagcgtcgcg gttactaaca ctcctctacc aggagcatcc
1380
gctactcccg
agctcagccc gcgtaagaaa ccgcgcaaga ccacgcgtcc tttcaaggtg
1440
attattaaac
cgcccgtgcc tcccgcgcct atcatgctgc cactcatcaa acaggaagac
1500
atcaagcccg
agcccgactt taccatccag taccgcaaca agattatcga taccgccggc 1560
tgtatcgtga
tctctgatag cgaggaagaa cagggtgaag aagtcgaaac ccgcggtgct
1620
accgcgtctt
caccttccac cggcagcggc acgccgcgag tgacctctcc cacgcacccg
1680
ctctcccaga
tgaaccaccc tcctcttccc gatcccttgg gccggcccga tgaagatagt
1740
tcctcttcgt
cttcctcctc ctgcagttcg gcttcggact cggagagtga gtccgaggag
1800
atgaaatgca
gcagtggcgg aggagcatcc gtgacctcga gccaccatgg gcgcggcgga
1860
tttggtggcg
cggcctcctc ctctctgctg agctgcggcc atcagagcag cggcggtgcg
1920
agcaccggac
ctcgcaagaa gaagagcaaa cgcatctccg agttggacaa cgagaaggtg
1980
cgcaatatca
tgaaagataa gaacactccc ttctgcacac ccaacgtgca gactcggcgt
2040
ggtcgcgtca
agattgacga ggtgagccgc atgttccgca acaccaatcg ctctcttgag
2100
tacaagaacc
tgcccttcac gattcccagt atgcaccagg tgttagatga ggccatcaaa
2160
gcctgcaaga
ccatgcaggt gaacaacaag ggcatccaga ttatctacac ccgcaatcat
2220
gaggtgaaga
gtgaggtgga tgcggtgcgg tgtcgcctgg gcaccatgtg caacctggcc
2280
ctctccactc
ccttcctcat ggagcacacc atgcccgtga cacatccacc cgaagtggcg
2340
cagcgcacag
ccgatgcttg taacgaaggc gtcaaggccg cgtggagcct caaagaattg
2400
cacacccacc
aattatgtcc tcgttcctcc gattaccgca acatgatcat ccacgctgcc
2460
acaccagtgg
acctgttggg cgctctcaac ctgtgcctgc cactgatgca gaagtttccc
2520
aaacaggtca
tggtgcgcat cttctccacc aaccagggtg ggttcatgct gcctatctac
2580
gagacggccg
cgaaggccta cgccgttggt cagtttgagc agcccaccga gacacctccc
2640
gaagacctgg
acaccctgag cctggccatc gaggcagcca tccaggacct gaggaacaag
2700
tctcagtaa
2709
<210>
4
<211>
902
<212>
PRT
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polypeptide IEfusion-VacO amino acid sequence
<400>
4
Met Val
Lys Gln Ile Lys Val Arg Val Asp Met Val Arg His Arg Ile
1
5 10
15
Lys Glu
His Met Leu Lys Lys Tyr Thr Gln Thr Glu Glu Lys Phe Thr
20
25
30
Gly Ala
Phe Asn Met Met Gly Gly Cys Leu Gln Asn Ala Leu Asp Ile
35 40
45
Leu Asp
Lys Val His Glu Pro Phe Glu Glu Met Lys Cys Ile Gly Leu
50
55
60
Thr Met
Gln Ser Met Tyr Glu Asn Tyr Ile Val Pro Glu Asp Lys Arg
65
70
75
80
Glu Met
Trp Met Ala Cys Ile Lys Glu Leu His Asp Val Ser Lys Gly
85
90
95
Ala Ala Asn
Lys Leu Gly Gly Ala Leu Gln Ala Lys Ala Arg Ala Lys
100
105
110
Lys Asp
Glu Leu Arg Arg Lys Met Met Tyr Met Cys Tyr Arg Asn Ile
115
120
125
Glu Phe
Phe Thr Lys Asn Ser Ala Phe Pro Lys Thr Thr Asn Gly Cys
130
135
140
Ser Gln Ala
Met Ala Ala Leu Gln Asn Leu Pro Gln Cys Ser Pro Asp
145
150
155
160
Glu Ile Met
Ala Tyr Ala Gln Lys Ile Phe Lys Ile Leu Asp Glu Glu
165
170
175
Arg Asp Lys
Val Leu Thr His Ile Asp His Ile Phe Met Asp Ile Leu
180
185
190
Thr Thr
Cys Val Glu Thr Met Cys Asn Glu Tyr Lys Val Thr Ser Asp
195
200
205
Ala Cys
Met Met Thr Met Tyr Gly Gly Ile Ser Leu Leu Ser Glu Phe
210
215
220
Cys Arg
Val Leu Cys Cys Tyr Val Leu Glu Glu Thr Ser Val Met Leu
225
230
235
240
Ala Lys
Arg Pro Leu Ile Thr Lys Pro Glu Val Ile Ser Val Met Lys
245
250
255
Arg Arg
Ile Glu Glu Ile Cys Met Lys Val Phe Ala Gln Tyr Ile Leu
260
265
270
Gly Ala Asp
Pro Leu Arg Val Cys Ser Pro Ser Val Asp Asp Leu Arg
275
280
285
Ala Ile Ala
Glu Glu Ser Asp Glu Glu Glu Ala Ile Val Ala Tyr Thr
290
295
300
Leu Ala Thr
Ala Gly Val Ser Ser Ser Asp Ser Leu Val Ser Pro Pro
305
310
315
320
Glu Ser Pro
Val Pro Ala Thr Ile Pro Leu Ser Ser Val Ile Val Ala
325
330
335
Glu Asn Ser
Asp Gln Glu Glu Ser Glu Gln Ser Asp Glu Glu Glu Glu
340
345
350
Glu Gly Ala
Gln Glu Glu Arg Glu Asp Thr Val Ser Val Lys Ser Glu
355
360
365
Pro Val Ser
Glu Ile Glu Glu Val Ala Pro Glu Glu Glu Glu Asp Gly
370
375
380
Ala Glu
Glu Pro Thr Ala Ser Gly Gly Lys Ser Thr His Pro Met Val
385
390
395
400
Thr Arg Ser
Lys Ala Asp Gln Gly Asp Ile Leu Ala Gln Ala Val Asn
405
410 415
His Ala
Gly Ile Asp Ser Ser Ser Thr Gly Pro Thr Leu Thr Thr His
420
425
430
Ser Cys Ser
Val Ser Ser Ala Pro Leu Asn Lys Pro Thr Pro Thr Ser
435
440 445
Val Ala Val
Thr Asn Thr Pro Leu Pro Gly Ala Ser Ala Thr Pro Glu
450
455
460
Leu Ser Pro
Arg Lys Lys Pro Arg Lys Thr Thr Arg Pro Phe Lys Val
465
470 475
480
Ile Ile Lys
Pro Pro Val Pro Pro Ala Pro Ile Met Leu Pro Leu Ile
485
490
495
Lys Gln Glu
Asp Ile Lys Pro Glu Pro Asp Phe Thr Ile Gln Tyr Arg
500 505
510
Asn Lys Ile
Ile Asp Thr Ala Gly Cys Ile Val Ile Ser Asp Ser Glu
515
520
525
Glu Glu Gln
Gly Glu Glu Val Glu Thr Arg Gly Ala Thr Ala Ser Ser
530
535
540
Pro Ser
Thr Gly Ser Gly Thr Pro Arg Val Thr Ser Pro Thr His Pro
545
550
555
560
Leu Ser Gln
Met Asn His Pro Pro Leu Pro Asp Pro Leu Gly Arg Pro
565
570
575
Asp Glu Asp
Ser Ser Ser Ser Ser Ser Ser Ser Cys Ser Ser Ala Ser
580
585
590
Asp Ser Glu
Ser Glu Ser Glu Glu Met Lys Cys Ser Ser Gly Gly Gly
595
600
605
Ala Ser
Val Thr Ser Ser His His Gly Arg Gly Gly Phe Gly Gly Ala
610
615
620
Ala Ser Ser
Ser Leu Leu Ser Cys Gly His Gln Ser Ser Gly Gly Ala
625
630
635
640
Ser Thr Gly
Pro Arg Lys Lys Lys Ser Lys Arg Ile Ser Glu Leu Asp
645
650
655
Asn Glu Lys
Val Arg Asn Ile Met Lys Asp Lys Asn Thr Pro Phe Cys
660
665
670
Thr Pro
Asn Val Gln Thr Arg Arg Gly Arg Val Lys Ile Asp Glu Val
675
680
685
Ser Arg
Met Phe Arg Asn Thr Asn Arg Ser Leu Glu Tyr Lys Asn Leu
690
695
700
Pro Phe
Thr Ile Pro Ser Met His Gln Val Leu Asp Glu Ala Ile Lys
705
710
715
720
Ala Cys
Lys Thr Met Gln Val Asn Asn Lys Gly Ile Gln Ile Ile Tyr
725
730
735
Thr Arg
Asn His Glu Val Lys Ser Glu Val Asp Ala Val Arg Cys Arg
740
745
750
Leu Gly
Thr Met Cys Asn Leu Ala Leu Ser Thr Pro Phe Leu Met Glu
755
760
765
His Thr
Met Pro Val Thr His Pro Pro Glu Val Ala Gln Arg Thr Ala
770
775
780
Asp Ala Cys
Asn Glu Gly Val Lys Ala Ala Trp Ser Leu Lys Glu Leu
785
790
795
800
His Thr
His Gln Leu Cys Pro Arg Ser Ser Asp Tyr Arg Asn Met Ile
805
810
815
Ile His Ala Ala
Thr Pro Val Asp Leu Leu Gly Ala Leu Asn Leu Cys
820
825
830
Leu Pro Leu
Met Gln Lys Phe Pro Lys Gln Val Met Val Arg Ile Phe
835
840
845
Ser Thr Asn
Gln Gly Gly Phe Met Leu Pro Ile Tyr Glu Thr Ala Ala
850
855
860
Lys Ala
Tyr Ala Val Gly Gln Phe Glu Gln Pro Thr Glu Thr Pro Pro
865
870
875
880
Glu Asp Leu
Asp Thr Leu Ser Leu Ala Ile Glu Ala Ala Ile Gln Asp
885
890
895
Leu Arg Asn
Lys Ser Gln
900
<210> 5
<211>
902
<212>
PRT
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polypeptide IEfusion amino acid sequence
<400>
5
Met Val
Lys Gln Ile Lys Val Arg Val Asp Met Val Arg His Arg Ile
1
5
10
15
Lys Glu
His Met Leu Lys Lys Tyr Thr Gln Thr Glu Glu Lys Phe Thr
20
25
30
Gly Ala
Phe Asn Met Met Gly Gly Cys Leu Gln Asn Ala Leu Asp Ile
35
40
45
Leu Asp
Lys Val His Glu Pro Phe Glu Glu Met Lys Cys Ile Gly Leu
50
55
60
Thr Met
Gln Ser Met Tyr Glu Asn Tyr Ile Val Pro Glu Asp Lys Arg
65
70
75
80
Glu Met
Trp Met Ala Cys Ile Lys Glu Leu His Asp Val Ser Lys Gly
85
90
95
Ala Ala Asn
Lys Leu Gly Gly Ala Leu Gln Ala Lys Ala Arg Ala Lys
100
105
110
Lys Asp
Glu Leu Arg Arg Lys Met Met Tyr Met Cys Tyr Arg Asn Ile
115
120
125
Glu Phe
Phe Thr Lys Asn Ser Ala Phe Pro Lys Thr Thr Asn Gly Cys
130
135
140
Ser Gln Ala
Met Ala Ala Leu Gln Asn Leu Pro Gln Cys Ser Pro Asp
145
150
155
160
Glu Ile Met
Ala Tyr Ala Gln Lys Ile Phe Lys Ile Leu Asp Glu Glu
165
170 175
Arg Asp Lys
Val Leu Thr His Ile Asp His Ile Phe Met Asp Ile Leu
180
185
190
Thr Thr
Cys Val Glu Thr Met Cys Asn Glu Tyr Lys Val Thr Ser Asp
195
200 205
Ala Cys
Met Met Thr Met Tyr Gly Gly Ile Ser Leu Leu Ser Glu Phe
210
215
220
Cys Arg
Val Leu Cys Cys Tyr Val Leu Glu Glu Thr Ser Val Met Leu
225
230 235
240
Ala Lys
Arg Pro Leu Ile Thr Lys Pro Glu Val Ile Ser Val Met Lys
245
250
255
Arg Arg
Ile Glu Glu Ile Cys Met Lys Val Phe Ala Gln Tyr Ile Leu
260
265
270
Gly Ala Asp
Pro Leu Arg Val Cys Ser Pro Ser Val Asp Asp Leu Arg
275
280
285
Ala Ile Ala
Glu Glu Ser Asp Glu Glu Glu Ala Ile Val Ala Tyr Thr
290 295
300
Leu Ala Thr
Ala Gly Val Ser Ser Ser Asp Ser Leu Val Ser Pro Pro
305
310
315
320
Glu Ser Pro
Val Pro Ala Thr Ile Pro Leu Ser Ser Val Ile Val Ala
325
330
335
Glu Asn Ser
Asp Gln Glu Glu Ser Glu Gln Ser Asp Glu Glu Glu Glu
340
345
350
Glu Gly Ala
Gln Glu Glu Arg Glu Asp Thr Val Ser Val Lys Ser Glu
355
360
365
Pro Val Ser
Glu Ile Glu Glu Val Ala Pro Glu Glu Glu Glu Asp Gly
370
375
380
Ala Glu
Glu Pro Thr Ala Ser Gly Gly Lys Ser Thr His Pro Met Val
385
390
395
400
Thr Arg Ser
Lys Ala Asp Gln Gly Asp Ile Leu Ala Gln Ala Val Asn
405
410
415
His Ala
Gly Ile Asp Ser Ser Ser Thr Gly Pro Thr Leu Thr Thr His
420
425
430
Ser Cys Ser
Val Ser Ser Ala Pro Leu Asn Lys Pro Thr Pro Thr Ser
435
440
445
Val Ala Val
Thr Asn Thr Pro Leu Pro Gly Ala Ser Ala Thr Pro Glu
450
455
460
Leu Ser Pro
Arg Lys Lys Pro Arg Lys Thr Thr Arg Pro Phe Lys Val
465
470
475
480
Ile Ile Lys
Pro Pro Val Pro Pro Ala Pro Ile Met Leu Pro Leu Ile
485
490
495
Lys Gln Glu
Asp Ile Lys Pro Glu Pro Asp Phe Thr Ile Gln Tyr Arg
500
505
510
Asn Lys Ile
Ile Asp Thr Ala Gly Cys Ile Val Ile Ser Asp Ser Glu
515
520
525
Glu Glu Gln
Gly Glu Glu Val Glu Thr Arg Gly Ala Thr Ala Ser Ser
530
535
540
Pro Ser
Thr Gly Ser Gly Thr Pro Arg Val Thr Ser Pro Thr His Pro
545
550
555
560
Leu Ser Gln
Met Asn His Pro Pro Leu Pro Asp Pro Leu Gly Arg Pro
565
570
575
Asp Glu Asp
Ser Ser Ser Ser Ser Ser Ser Ser Cys Ser Ser Ala Ser
580
585
590
Asp Ser Glu
Ser Glu Ser Glu Glu Met Lys Cys Ser Ser Gly Gly Gly
595
600
605
Ala Ser
Val Thr Ser Ser His His Gly Arg Gly Gly Phe Gly Gly Ala
610
615
620
Ala Ser Ser
Ser Leu Leu Ser Cys Gly His Gln Ser Ser Gly Gly Ala
625
630
635
640
Ser Thr Gly
Pro Arg Lys Lys Lys Ser Lys Arg Ile Ser Glu Leu Asp
645
650
655
Asn Glu Lys
Val Arg Asn Ile Met Lys Asp Lys Asn Thr Pro Phe Cys
660
665
670
Thr Pro
Asn Val Gln Thr Arg Arg Gly Arg Val Lys Ile Asp Glu Val
675
680
685
Ser Arg
Met Phe Arg Asn Thr Asn Arg Ser Leu Glu Tyr Lys Asn Leu
690
695
700
Pro Phe
Thr Ile Pro Ser Met His Gln Val Leu Asp Glu Ala Ile Lys
705
710
715
720
Ala Cys
Lys Thr Met Gln Val Asn Asn Lys Gly Ile Gln Ile Ile Tyr
725
730
735
Thr Arg
Asn His Glu Val Lys Ser Glu Val Asp Ala Val Arg Cys Arg
740
745
750
Leu Gly
Thr Met Cys Asn Leu Ala Leu Ser Thr Pro Phe Leu Met Glu
755
760
765
His Thr
Met Pro Val Thr His Pro Pro Glu Val Ala Gln Arg Thr Ala
770
775
780
Asp Ala Cys
Asn Glu Gly Val Lys Ala Ala Trp Ser Leu Lys Glu Leu
785
790
795
800
His Thr
His Gln Leu Cys Pro Arg Ser Ser Asp Tyr Arg Asn Met Ile
805
810
815
Ile His Ala
Ala Thr Pro Val Asp Leu Leu Gly Ala Leu Asn Leu Cys
820
825
830
Leu Pro Leu
Met Gln Lys Phe Pro Lys Gln Val Met Val Arg Ile Phe
835
840
845
Ser Thr Asn
Gln Gly Gly Phe Met Leu Pro Ile Tyr Glu Thr Ala Ala
850
855
860
Lys Ala
Tyr Ala Val Gly Gln Phe Glu Gln Pro Thr Glu Thr Pro Pro
865
870
875
880
Glu Asp Leu
Asp Thr Leu Ser Leu Ala Ile Glu Ala Ala Ile Gln Asp
885
890
895
Leu Arg Asn
Lys Ser Gln
900
<210> 6
<211>
902
<212>
PRT
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polypeptide IEfusion-4NT amino acid sequence
<400>
6
Met Val
Lys Gln Ile Lys Val Arg Val Asp Met Val Arg His Arg Ile
1
5
10
15
Lys Glu
His Met Leu Lys Lys Tyr Thr Gln Thr Glu Glu Lys Phe Thr
20 25
30
Gly Ala
Phe Asn Met Met Gly Gly Cys Leu Gln Asn Ala Leu Asp Ile
35
40
45
Leu Asp
Lys Val His Glu Pro Phe Glu Glu Met Lys Cys Ile Gly Leu
50 55
60
Thr Met
Gln Ser Met Tyr Glu Asn Tyr Ile Val Pro Glu Asp Lys Arg
65
70
75
80
Glu Met
Trp Met Ala Cys Ile Lys Glu Leu His Asp Val Ser Lys Gly
85
90
95
Ala Ala Asn
Lys Leu Gly Gly Ala Leu Gln Ala Lys Ala Arg Ala Lys
100
105
110
Lys Asp
Glu Leu Arg Arg Lys Met Met Tyr Met Cys Tyr Arg Asn Ile
115
120
125
Glu Phe
Phe Thr Lys Asn Ser Ala Phe Pro Lys Thr Thr Asn Gly Cys
130
135
140
Ser Gln Ala
Met Ala Ala Leu Gln Asn Leu Pro Gln Cys Ser Pro Asp
145
150
155
160
Glu Ile Met
Ala Tyr Ala Gln Lys Ile Phe Lys Ile Leu Asp Glu Glu
165
170
175
Arg Asp Lys
Val Leu Thr His Ile Asp His Ile Phe Met Asp Ile Leu
180
185
190
Thr Thr
Cys Val Glu Thr Met Cys Asn Glu Tyr Lys Val Thr Ser Asp
195
200
205
Ala Cys
Met Met Thr Met Tyr Gly Gly Ile Ser Leu Leu Ser Glu Phe
210
215
220
Cys Arg
Val Leu Cys Cys Tyr Val Leu Glu Glu Thr Ser Val Met Leu
225
230
235
240
Ala Lys
Arg Pro Leu Ile Thr Lys Pro Glu Val Ile Ser Val Met Lys
245
250
255
Arg Arg
Ile Glu Glu Ile Cys Met Lys Val Phe Ala Gln Tyr Ile Leu
260
265
270
Gly Ala Asp
Pro Leu Arg Val Cys Ser Pro Ser Val Asp Asp Leu Arg
275
280
285
Ala Ile Ala
Glu Glu Ser Asp Glu Glu Glu Ala Ile Val Ala Tyr Thr
290
295
300
Leu Ala Thr
Ala Gly Val Ser Ser Ser Asp Ser Leu Val Ser Pro Pro
305
310
315
320
Glu Ser Pro
Val Pro Ala Thr Ile Pro Leu Ser Ser Val Ile Val Ala
325
330
335
Glu Asn Ser
Asp Gln Glu Glu Ser Glu Gln Ser Asp Glu Glu Glu Glu
340
345
350
Glu Gly Ala
Gln Glu Glu Arg Glu Asp Thr Val Ser Val Lys Ser Glu
355
360
365
Pro Val Ser
Glu Ile Glu Glu Val Ala Pro Glu Glu Glu Glu Asp Gly
370
375
380
Ala Glu
Glu Pro Thr Ala Ser Gly Gly Lys Ser Thr His Pro Met Val
385
390
395
400
Thr Arg Ser
Lys Ala Asp Gln Gly Asp Ile Leu Ala Gln Ala Val Asn
405
410
415
His Ala
Gly Ile Asp Ser Ser Ser Thr Gly Pro Thr Leu Thr Thr His
420
425
430
Ser Cys Ser
Val Ser Ser Ala Pro Leu Asn Lys Pro Thr Pro Thr Ser
435
440
445
Val Ala Val
Thr Asn Thr Pro Leu Pro Gly Ala Ser Ala Thr Pro Glu
450
455
460
Leu Ser Pro
Arg Lys Lys Pro Arg Lys Thr Thr Arg Pro Phe Lys Val
465
470
475
480
Ile Ile Lys
Pro Pro Val Pro Pro Ala Pro Ile Met Leu Pro Leu Ile
485
490
495
Lys Gln Glu
Asp Ile Lys Pro Glu Pro Asp Phe Thr Ile Gln Tyr Arg
500
505
510
Asn Lys Ile
Ile Asp Thr Ala Gly Cys Ile Val Ile Ser Asp Ser Glu
515
520
525
Glu Glu Gln
Gly Glu Glu Val Glu Thr Arg Gly Ala Thr Ala Ser Ser
530
535
540
Pro Ser
Thr Gly Ser Gly Thr Pro Arg Val Thr Ser Pro Thr His Pro
545
550
555
560
Leu Ser Gln
Met Asn His Pro Pro Leu Pro Asp Pro Leu Gly Arg Pro
565
570
575
Asp Glu Asp
Ser Ser Ser Ser Ser Ser Ser Ser Cys Ser Ser Ala Ser
580
585
590
Asp Ser Glu
Ser Glu Ser Glu Glu Met Lys Cys Ser Ser Gly Gly Gly
595
600
605
Ala Ser
Val Thr Ser Ser His His Gly Arg Gly Gly Phe Gly Gly Ala
610
615
620
Ala Ser Ser
Ser Leu Leu Ser Cys Gly His Gln Ser Ser Gly Gly Ala
625
630
635
640
Ser Thr Gly
Pro Arg Lys Lys Lys Ser Lys Arg Ile Ser Glu Leu Asp
645
650
655
Asn Glu Lys
Val Arg Asn Ile Met Lys Asp Lys Asn Thr Pro Phe Cys
660
665
670
Thr Pro
Asn Val Gln Thr Arg Arg Gly Arg Val Lys Ile Asp Glu Val
675
680
685
Ser Arg
Met Phe Arg Asn Thr Asn Arg Ser Leu Glu Tyr Lys Asn Leu
690
695
700
Pro Phe
Thr Ile Pro Ser Met His Gln Val Leu Asp Glu Ala Ile Lys
705
710
715
720
Ala Cys
Lys Thr Met Gln Val Asn Asn Lys Gly Ile Gln Ile Ile Tyr
725
730
735
Thr Arg
Asn His Glu Val Lys Ser Glu Val Asp Ala Val Arg Cys Arg
740
745
750
Leu Gly
Thr Met Cys Asn Leu Ala Leu Ser Thr Pro Phe Leu Met Glu
755
760
765
His Thr
Met Pro Val Thr His Pro Pro Glu Val Ala Gln Arg Thr Ala
770
775
780
Asp Ala Cys
Asn Glu Gly Val Lys Ala Ala Trp Ser Leu Lys Glu Leu
785
790
795
800
His Thr
His Gln Leu Cys Pro Arg Ser Ser Asp Tyr Arg Asn Met Ile
805
810
815
Ile His Ala
Ala Thr Pro Val Asp Leu Leu Gly Ala Leu Asn Leu Cys
820
825
830
Leu Pro Leu
Met Gln Lys Phe Pro Lys Gln Val Met Val Arg Ile Phe
835
840
845
Ser Thr Asn
Gln Gly Gly Phe Met Leu Pro Ile Tyr Glu Thr Ala Ala
850
855
860
Lys Ala
Tyr Ala Val Gly Gln Phe Glu Gln Pro Thr Glu Thr Pro Pro
865
870
875
880
Glu Asp Leu
Asp Thr Leu Ser Leu Ala Ile Glu Ala Ala Ile Gln Asp
885
890
895
Leu Arg Asn
Lys Ser Gln
900
<210> 7
<211>
1491
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE2-VacO DNA sequence
<400>
7
atgggagaca
tcctagcaca agcagtgaac catgctggaa ttgactcatc
ttcgaccgga 60
ccaactctaa
cgactcattc atgttcggtt agttctgctc ctcttaacaa
gcctacacct 120
acctcggtag
ctgttaccaa cacaccttta ccaggagcat cagcaacacc
tgagttgtct 180
ccaagaaaga
agcctcgtaa gaccacgaga ccgttcaagg tgatcatcaa gccaccagta
240
ccacctgctc
cgatcatgtt gccattgatc aagcaggagg acattaagcc
agaacctgac 300
ttcacgatac
agtaccgtaa caagatcata gatacagcag gatgcatagt
gatctcagat 360
agtgaagagg
agcaaggtga ggaagtggag actagaggag ccacagccag
ttcgccttcc 420
acaggatccg
gaactcctag agtaactagt ccgacacatc cactttccca
gatgaatcat 480
ccacctctac
cggatcctct aggacgacca gatgaagatt cttcttcatc
tagttcaagt 540
tcttgctcat
ccgcgagtga tagtgagtca gaaagtgaag agatgaagtg
ctcttctggt 600
ggtggagcta
gtgtcacttc atctcatcat ggacgaggag gatttggagg
tgctgcgagt 660
agttccttac
taagttgtgg acatcagtca tctggtggtg catctactgg
acctagaaag 720
aagaagtcaa
agagaatctc cgaattggat aatgagaaag tgagaaacat
catgaaggac 780
aagaacacgc
cgttctgcac tccgaatgtt cagacgagaa gaggacgagt gaagatagat 840
gaagtatcac
gaatgttcag aaacacaaat cgttctctag agtacaagaa
tcttccgttc 900
accatacctt
cgatgcacca agtattagat gaggctatca aggcatgtaa
gaccatgcaa 960
gttaacaaca
aaggaataca gatcatctac actagaaacc atgaggttaa gagtgaggtg
1020
gatgccgtac
gttgtagatt gggaacgatg tgtaaccttg cgctatctac tcctttccta
1080
atggagcata
ctatgcctgt gactcatcct cctgaagtgg ctcaaagaac agctgatgct
1140
tgtaacgaag
gtgtgaaagc tgcttggtcc ctaaaggagt tacatacaca ccaactttgt
1200
ccacgatcca
gtgactacag aaacatgatc attcatgcag ctacgcctgt agatctactt
1260
ggagctctta
acctatgtct tcctttgatg cagaagttcc ctaagcaagt gatggtgaga
1320
atcttctcga
cgaatcaagg aggattcatg ttaccgatat acgagacagc tgcaaaggct
1380
tacgctgtcg
gtcagttcga gcaaccgact gaaacgcctc ctgaggactt agatacattg
1440
tctttggcga
tagaagcagc gattcaggat cttagaaaca agagtcagta
a
1491
<210>
8
<211>
1491
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE2 DNA sequence
<400>
8
atgggtgaca
tcctcgccca ggctgtcaat catgccggta tcgattccag
tagcaccggc 60
cccacgctga
caacccactc ttgcagcgtt agcagcgccc ctcttaacaa
gccgaccccc 120
accagcgtcg
cggttactaa cactcctctc cccggggcat ccgctactcc
cgagctcagc 180
ccgcgtaaga
aaccgcgcaa aaccacgcgt cctttcaagg tgattattaa
accgcccgtg 240
cctcccgcgc
ctatcatgct gcccctcatc aaacaggaag acatcaagcc
cgagcccgac 300
tttaccatcc
agtaccgcaa caagattatc gataccgccg gctgtatcgt
gatctctgat 360
agcgaggaag
aacagggtga agaagtcgaa acccgcggtg ctaccgcgtc
ttccccttcc 420
accggcagcg
gcacgccgcg agtgacctct cccacgcacc cgctctccca
gatgaaccac 480
cctcctcttc
ccgatccctt gggccggccc gatgaagata gttcctcttc
gtcttcctcc 540
tcctgcagtt
cggcttcgga ctcggagagt gagtccgagg agatgaaatg
cagcagtggc 600
ggaggagcat
ccgtgacctc gagccaccat gggcgcggcg gttttggtgg
cgcggcctcc 660
tcctctctgc
tgagctgcgg ccatcagagc agcggcgggg cgagcaccgg
accccgcaag 720
aagaagagca
aacgcatctc cgagttggac aacgagaagg tgcgcaatat
catgaaagat 780
aagaacaccc
ccttctgcac acccaacgtg cagactcggc ggggtcgcgt
caagattgac 840
gaggtgagcc
gcatgttccg caacaccaat cgctctcttg agtacaagaa
cctgcccttc 900
acgattccca
gtatgcacca ggtgttagat gaggccatca aagcctgcaa
aaccatgcag 960
gtgaacaaca
agggcatcca gattatctac acccgcaatc atgaggtgaa gagtgaggtg
1020
gatgcggtgc
ggtgtcgcct gggcaccatg tgcaacctgg ccctctccac tcccttcctc
1080
atggagcaca
ccatgcccgt gacacatcca cccgaagtgg cgcagcgcac agccgatgct
1140
tgtaacgaag
gcgtcaaggc cgcgtggagc ctcaaagaat tgcacaccca ccaattatgc
1200
ccccgttcct
ccgattaccg caacatgatc atccacgctg ccacccccgt ggacctgttg
1260
ggcgctctca
acctgtgcct gcccctgatg caaaagtttc ccaaacaggt catggtgcgc
1320
atcttctcca
ccaaccaggg tgggttcatg ctgcctatct acgagacggc cgcgaaggcc
1380
tacgccgtgg
ggcagtttga gcagcccacc gagacccctc ccgaagacct ggacaccctg
1440
agcctggcca
tcgaggcagc catccaggac ctgaggaaca agtctcagta
a
1491
<210>
9
<211>
1491
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE2-4nt DNA sequence
<400>
9
atgggtgaca
tcctcgccca ggctgtcaat catgccggta tcgattccag
tagcaccgga 60
cctacgctga
caacccactc ttgcagcgtt agcagcgctc ctcttaacaa
gccgactcca 120
accagcgtcg
cggttactaa cactcctcta ccaggagcat ccgctactcc
cgagctcagc 180
ccgcgtaaga
aaccgcgcaa gaccacgcgt cctttcaagg tgattattaa
accgcccgtg 240
cctcccgcgc
ctatcatgct gccactcatc aaacaggaag acatcaagcc
cgagcccgac 300
tttaccatcc
agtaccgcaa caagattatc gataccgccg gctgtatcgt
gatctctgat 360
agcgaggaag
aacagggtga agaagtcgaa acccgcggtg ctaccgcgtc ttcaccttcc
420
accggcagcg
gcacgccgcg agtgacctct cccacgcacc cgctctccca
gatgaaccac 480
cctcctcttc
ccgatccctt gggccggccc gatgaagata gttcctcttc
gtcttcctcc 540
tcctgcagtt
cggcttcgga ctcggagagt gagtccgagg agatgaaatg
cagcagtggc 600
ggaggagcat
ccgtgacctc gagccaccat gggcgcggcg gatttggtgg
cgcggcctcc 660
tcctctctgc
tgagctgcgg ccatcagagc agcggcggtg cgagcaccgg
acctcgcaag 720
aagaagagca
aacgcatctc cgagttggac aacgagaagg tgcgcaatat
catgaaagat 780
aagaacactc
ccttctgcac acccaacgtg cagactcggc gtggtcgcgt
caagattgac 840
gaggtgagcc
gcatgttccg caacaccaat cgctctcttg agtacaagaa
cctgcccttc 900
acgattccca
gtatgcacca ggtgttagat gaggccatca aagcctgcaa
gaccatgcag 960
gtgaacaaca
agggcatcca gattatctac acccgcaatc atgaggtgaa gagtgaggtg
1020
gatgcggtgc
ggtgtcgcct gggcaccatg tgcaacctgg ccctctccac tcccttcctc
1080
atggagcaca
ccatgcccgt gacacatcca cccgaagtgg cgcagcgcac agccgatgct
1140
tgtaacgaag
gcgtcaaggc cgcgtggagc ctcaaagaat tgcacaccca ccaattatgt
1200
cctcgttcct
ccgattaccg caacatgatc atccacgctg ccacaccagt ggacctgttg
1260
ggcgctctca
acctgtgcct gccactgatg cagaagtttc ccaaacaggt catggtgcgc
1320
atcttctcca
ccaaccaggg tgggttcatg ctgcctatct acgagacggc cgcgaaggcc
1380
tacgccgttg
gtcagtttga gcagcccacc gagacacctc ccgaagacct ggacaccctg
1440
agcctggcca
tcgaggcagc catccaggac ctgaggaaca agtctcagta
a
1491
<210>
10
<211>
1491
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE2 4nt H363A
DNA sequence
<400>
10
atgggtgaca
tcctcgccca ggctgtcaat catgccggta tcgattccag
tagcaccgga 60
cctacgctga
caacccactc ttgcagcgtt agcagcgctc ctcttaacaa
gccgactcca 120
accagcgtcg
cggttactaa cactcctcta ccaggagcat ccgctactcc
cgagctcagc 180
ccgcgtaaga
aaccgcgcaa gaccacgcgt cctttcaagg tgattattaa
accgcccgtg 240
cctcccgcgc
ctatcatgct gccactcatc aaacaggaag acatcaagcc
cgagcccgac 300
tttaccatcc
agtaccgcaa caagattatc gataccgccg gctgtatcgt
gatctctgat 360
agcgaggaag
aacagggtga agaagtcgaa acccgcggtg ctaccgcgtc
ttcaccttcc 420
accggcagcg
gcacgccgcg agtgacctct cccacgcacc cgctctccca
gatgaaccac 480
cctcctcttc
ccgatccctt gggccggccc gatgaagata gttcctcttc
gtcttcctcc 540
tcctgcagtt
cggcttcgga ctcggagagt gagtccgagg agatgaaatg cagcagtggc
600
ggaggagcat
ccgtgacctc gagccaccat gggcgcggcg gatttggtgg
cgcggcctcc 660
tcctctctgc
tgagctgcgg ccatcagagc agcggcggtg cgagcaccgg
acctcgcaag 720
aagaagagca
aacgcatctc cgagttggac aacgagaagg tgcgcaatat
catgaaagat 780
aagaacactc
ccttctgcac acccaacgtg cagactcggc gtggtcgcgt
caagattgac 840
gaggtgagcc
gcatgttccg caacaccaat cgctctcttg agtacaagaa
cctgcccttc 900
acgattccca
gtatgcacca ggtgttagat gaggccatca aagcctgcaa
gaccatgcag 960
gtgaacaaca
agggcatcca gattatctac acccgcaatc atgaggtgaa gagtgaggtg
1020
gatgcggtgc
ggtgtcgcct gggcaccatg tgcaacctgg ccctctccac tcccttcctc
1080
atggaggcaa
ccatgcccgt gacacatcca cccgaagtgg cgcagcgcac agccgatgct
1140
tgtaacgaag
gcgtcaaggc cgcgtggagc ctcaaagaat tgcacaccca ccaattatgt 1200
cctcgttcct
ccgattaccg caacatgatc atccacgctg ccacaccagt ggacctgttg
1260
ggcgctctca
acctgtgcct gccactgatg cagaagtttc ccaaacaggt catggtgcgc
1320
atcttctcca
ccaaccaggg tgggttcatg ctgcctatct acgagacggc cgcgaaggcc
1380
tacgccgttg
gtcagtttga gcagcccacc gagacacctc ccgaagacct ggacaccctg
1440
agcctggcca
tcgaggcagc catccaggac ctgaggaaca agtctcagta
a
1491
<210>
11
<211>
1491
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE2 4nt H369A
DNA sequence
<400>
11
atgggtgaca
tcctcgccca ggctgtcaat catgccggta tcgattccag
tagcaccgga 60
cctacgctga
caacccactc ttgcagcgtt agcagcgctc ctcttaacaa
gccgactcca 120
accagcgtcg
cggttactaa cactcctcta ccaggagcat ccgctactcc
cgagctcagc 180
ccgcgtaaga
aaccgcgcaa gaccacgcgt cctttcaagg tgattattaa
accgcccgtg 240
cctcccgcgc
ctatcatgct gccactcatc aaacaggaag acatcaagcc
cgagcccgac 300
tttaccatcc
agtaccgcaa caagattatc gataccgccg gctgtatcgt
gatctctgat 360
agcgaggaag
aacagggtga agaagtcgaa acccgcggtg ctaccgcgtc
ttcaccttcc 420
accggcagcg
gcacgccgcg agtgacctct cccacgcacc cgctctccca
gatgaaccac 480
cctcctcttc
ccgatccctt gggccggccc gatgaagata gttcctcttc
gtcttcctcc 540
tcctgcagtt
cggcttcgga ctcggagagt gagtccgagg agatgaaatg
cagcagtggc 600
ggaggagcat
ccgtgacctc gagccaccat gggcgcggcg gatttggtgg
cgcggcctcc 660
tcctctctgc
tgagctgcgg ccatcagagc agcggcggtg cgagcaccgg
acctcgcaag 720
aagaagagca
aacgcatctc cgagttggac aacgagaagg tgcgcaatat catgaaagat
780
aagaacactc
ccttctgcac acccaacgtg cagactcggc gtggtcgcgt
caagattgac 840
gaggtgagcc
gcatgttccg caacaccaat cgctctcttg agtacaagaa
cctgcccttc 900
acgattccca
gtatgcacca ggtgttagat gaggccatca aagcctgcaa
gaccatgcag 960
gtgaacaaca agggcatcca
gattatctac acccgcaatc atgaggtgaa gagtgaggtg 1020
gatgcggtgc
ggtgtcgcct gggcaccatg tgcaacctgg ccctctccac tcccttcctc
1080
atggagcaca
ccatgcccgt gacagcacca cccgaagtgg cgcagcgcac agccgatgct
1140
tgtaacgaag
gcgtcaaggc cgcgtggagc ctcaaagaat tgcacaccca ccaattatgt
1200
cctcgttcct
ccgattaccg caacatgatc atccacgctg ccacaccagt ggacctgttg
1260
ggcgctctca
acctgtgcct gccactgatg cagaagtttc ccaaacaggt catggtgcgc
1320
atcttctcca
ccaaccaggg tgggttcatg ctgcctatct acgagacggc cgcgaaggcc 1380
tacgccgttg
gtcagtttga gcagcccacc gagacacctc ccgaagacct ggacaccctg
1440
agcctggcca
tcgaggcagc catccaggac ctgaggaaca agtctcagta
a
1491
<210>
12
<211>
1491
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE2 4nt
H363A/H369A DNA sequence
<400>
12
atgggtgaca
tcctcgccca ggctgtcaat catgccggta tcgattccag
tagcaccgga 60
cctacgctga
caacccactc ttgcagcgtt agcagcgctc ctcttaacaa
gccgactcca 120
accagcgtcg
cggttactaa cactcctcta ccaggagcat ccgctactcc
cgagctcagc 180
ccgcgtaaga
aaccgcgcaa gaccacgcgt cctttcaagg tgattattaa
accgcccgtg 240
cctcccgcgc
ctatcatgct gccactcatc aaacaggaag acatcaagcc
cgagcccgac 300
tttaccatcc
agtaccgcaa caagattatc gataccgccg gctgtatcgt
gatctctgat 360
agcgaggaag
aacagggtga agaagtcgaa acccgcggtg ctaccgcgtc
ttcaccttcc 420
accggcagcg
gcacgccgcg agtgacctct cccacgcacc cgctctccca
gatgaaccac 480
cctcctcttc
ccgatccctt gggccggccc gatgaagata gttcctcttc
gtcttcctcc 540
tcctgcagtt
cggcttcgga ctcggagagt gagtccgagg agatgaaatg
cagcagtggc 600
ggaggagcat
ccgtgacctc gagccaccat gggcgcggcg gatttggtgg
cgcggcctcc 660
tcctctctgc
tgagctgcgg ccatcagagc agcggcggtg cgagcaccgg
acctcgcaag 720
aagaagagca
aacgcatctc cgagttggac aacgagaagg tgcgcaatat
catgaaagat 780
aagaacactc
ccttctgcac acccaacgtg cagactcggc gtggtcgcgt
caagattgac 840
gaggtgagcc
gcatgttccg caacaccaat cgctctcttg agtacaagaa
cctgcccttc 900
acgattccca
gtatgcacca ggtgttagat gaggccatca aagcctgcaa gaccatgcag
960
gtgaacaaca
agggcatcca gattatctac acccgcaatc atgaggtgaa gagtgaggtg
1020
gatgcggtgc
ggtgtcgcct gggcaccatg tgcaacctgg ccctctccac tcccttcctc
1080
atggaggcaa
ccatgcccgt gacagcacca cccgaagtgg cgcagcgcac agccgatgct
1140
tgtaacgaag
gcgtcaaggc cgcgtggagc ctcaaagaat tgcacaccca ccaattatgt
1200
cctcgttcct
ccgattaccg caacatgatc atccacgctg ccacaccagt ggacctgttg
1260
ggcgctctca
acctgtgcct gccactgatg cagaagtttc ccaaacaggt catggtgcgc
1320
atcttctcca
ccaaccaggg tgggttcatg ctgcctatct acgagacggc cgcgaaggcc
1380
tacgccgttg
gtcagtttga gcagcccacc gagacacctc ccgaagacct ggacaccctg
1440
agcctggcca
tcgaggcagc catccaggac ctgaggaaca agtctcagta
a
1491
<210>
13
<211>
1488
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE2 H363A DNA
sequence
<400>
13
atgggtgaca
tcctcgccca ggctgtcaat catgccggta tcgattccag
tagcaccggc 60
cccacgctga
caacccactc ttgcagcgtt agcagcgccc ctcttaacaa
gccgaccccc 120
accagcgtcg
cggttactaa cactcctctc cccggggcat ccgctactcc
cgagctcagc 180
ccgcgtaaga
aaccgcgcaa aaccacgcgt cctttcaagg tgattattaa
accgcccgtg 240
cctcccgcgc
ctatcatgct gcccctcatc aaacaggaag acatcaagcc
cgagcccgac 300
tttaccatcc
agtaccgcaa caagattatc gataccgccg gctgtatcgt
gatctctgat 360
agcgaggaag
aacagggtga agaagtcgaa acccgcggtg ctaccgcgtc
ttccccttcc 420
accggcagcg
gcacgccgcg agtgacctct cccacgcacc cgctctccca
gatgaaccac 480
cctcctcttc
ccgatccctt gggccggccc gatgaagata gttcctcttc
gtcttcctcc 540
tcctgcagtt
cggcttcgga ctcggagagt gagtccgagg agatgaaatg
cagcagtggc 600
ggaggagcat
ccgtgacctc gagccaccat gggcgcggcg gttttggtgg
cgcggcctcc 660
tcctctctgc
tgagctgcgg ccatcagagc agcggcgggg cgagcaccgg
accccgcaag 720
aagaagagca
aacgcatctc cgagttggac aacgagaagg tgcgcaatat
catgaaagat 780
aagaacaccc
ccttctgcac acccaacgtg cagactcggc ggggtcgcgt
caagattgac 840
gaggtgagcc
gcatgttccg caacaccaat cgctctcttg agtacaagaa
cctgcccttc 900
acgattccca
gtatgcacca ggtgttagat gaggccatca aagcctgcaa
aaccatgcag 960
gtgaacaaca
agggcatcca gattatctac acccgcaatc atgaggtgaa gagtgaggtg
1020
gatgcggtgc
ggtgtcgcct gggcaccatg tgcaacctgg ccctctccac tcccttcctc
1080
atggaggcaa
ccatgcccgt gacacatcca cccgaagtgg cgcagcgcac agccgatgct
1140
tgtaacgaag
gcgtcaaggc cgcgtggagc ctcaaagaat tgcacaccca ccaattatgc
1200
ccccgttcct
ccgattaccg caacatgatc atccacgctg ccacccccgt ggacctgttg
1260
ggcgctctca
acctgtgcct gcccctgatg caaaagtttc ccaaacaggt catggtgcgc
1320
atcttctcca
ccaaccaggg tgggttcatg ctgcctatct acgagacggc cgcgaaggcc
1380
tacgccgtgg
ggcagtttga gcagcccacc gagacccctc ccgaagacct ggacaccctg
1440
agcctggcca
tcgaggcagc catccaggac ctgaggaaca
agtctcag
1488
<210>
14
<211>
1488
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE2 H369A DNA
sequence
<400>
14
atgggtgaca
tcctcgccca ggctgtcaat catgccggta tcgattccag
tagcaccggc 60
cccacgctga
caacccactc ttgcagcgtt agcagcgccc ctcttaacaa
gccgaccccc 120
accagcgtcg
cggttactaa cactcctctc cccggggcat ccgctactcc
cgagctcagc 180
ccgcgtaaga
aaccgcgcaa aaccacgcgt cctttcaagg tgattattaa
accgcccgtg 240
cctcccgcgc
ctatcatgct gcccctcatc aaacaggaag acatcaagcc
cgagcccgac 300
tttaccatcc
agtaccgcaa caagattatc gataccgccg gctgtatcgt
gatctctgat 360
agcgaggaag
aacagggtga agaagtcgaa acccgcggtg ctaccgcgtc
ttccccttcc 420
accggcagcg
gcacgccgcg agtgacctct cccacgcacc cgctctccca
gatgaaccac 480
cctcctcttc
ccgatccctt gggccggccc gatgaagata gttcctcttc
gtcttcctcc 540
tcctgcagtt
cggcttcgga ctcggagagt gagtccgagg agatgaaatg
cagcagtggc 600
ggaggagcat
ccgtgacctc gagccaccat gggcgcggcg gttttggtgg
cgcggcctcc 660
tcctctctgc
tgagctgcgg ccatcagagc agcggcgggg cgagcaccgg accccgcaag
720
aagaagagca
aacgcatctc cgagttggac aacgagaagg tgcgcaatat
catgaaagat 780
aagaacaccc
ccttctgcac acccaacgtg cagactcggc ggggtcgcgt
caagattgac 840
gaggtgagcc
gcatgttccg caacaccaat cgctctcttg agtacaagaa
cctgcccttc 900
acgattccca gtatgcacca
ggtgttagat gaggccatca aagcctgcaa aaccatgcag 960
gtgaacaaca
agggcatcca gattatctac acccgcaatc atgaggtgaa gagtgaggtg
1020
gatgcggtgc
ggtgtcgcct gggcaccatg tgcaacctgg ccctctccac tcccttcctc
1080
atggagcaca
ccatgcccgt gacagcacca cccgaagtgg cgcagcgcac agccgatgct
1140
tgtaacgaag
gcgtcaaggc cgcgtggagc ctcaaagaat tgcacaccca ccaattatgc
1200
ccccgttcct
ccgattaccg caacatgatc atccacgctg ccacccccgt ggacctgttg
1260
ggcgctctca
acctgtgcct gcccctgatg caaaagtttc ccaaacaggt catggtgcgc 1320
atcttctcca
ccaaccaggg tgggttcatg ctgcctatct acgagacggc cgcgaaggcc
1380
tacgccgtgg
ggcagtttga gcagcccacc gagacccctc ccgaagacct ggacaccctg
1440
agcctggcca
tcgaggcagc catccaggac ctgaggaaca
agtctcag
1488
<210>
15
<211>
1488
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE2
H363A/H369A DNA sequence
<400>
15
atgggtgaca
tcctcgccca ggctgtcaat catgccggta tcgattccag
tagcaccggc 60
cccacgctga
caacccactc ttgcagcgtt agcagcgccc ctcttaacaa
gccgaccccc 120
accagcgtcg
cggttactaa cactcctctc cccggggcat ccgctactcc
cgagctcagc 180
ccgcgtaaga
aaccgcgcaa aaccacgcgt cctttcaagg tgattattaa
accgcccgtg 240
cctcccgcgc
ctatcatgct gcccctcatc aaacaggaag acatcaagcc
cgagcccgac 300
tttaccatcc
agtaccgcaa caagattatc gataccgccg gctgtatcgt
gatctctgat 360
agcgaggaag
aacagggtga agaagtcgaa acccgcggtg ctaccgcgtc
ttccccttcc 420
accggcagcg
gcacgccgcg agtgacctct cccacgcacc cgctctccca
gatgaaccac 480
cctcctcttc
ccgatccctt gggccggccc gatgaagata gttcctcttc
gtcttcctcc 540
tcctgcagtt
cggcttcgga ctcggagagt gagtccgagg agatgaaatg
cagcagtggc 600
ggaggagcat
ccgtgacctc gagccaccat gggcgcggcg gttttggtgg
cgcggcctcc 660
tcctctctgc
tgagctgcgg ccatcagagc agcggcgggg cgagcaccgg
accccgcaag 720
aagaagagca
aacgcatctc cgagttggac aacgagaagg tgcgcaatat
catgaaagat 780
aagaacaccc
ccttctgcac acccaacgtg cagactcggc ggggtcgcgt
caagattgac 840
gaggtgagcc
gcatgttccg caacaccaat cgctctcttg agtacaagaa cctgcccttc
900
acgattccca
gtatgcacca ggtgttagat gaggccatca aagcctgcaa
aaccatgcag 960
gtgaacaaca
agggcatcca gattatctac acccgcaatc atgaggtgaa gagtgaggtg
1020
gatgcggtgc
ggtgtcgcct gggcaccatg tgcaacctgg ccctctccac tcccttcctc
1080
atggaggcaa ccatgcccgt
gacagcacca cccgaagtgg cgcagcgcac agccgatgct 1140
tgtaacgaag
gcgtcaaggc cgcgtggagc ctcaaagaat tgcacaccca ccaattatgc
1200
ccccgttcct
ccgattaccg caacatgatc atccacgctg ccacccccgt ggacctgttg
1260
ggcgctctca
acctgtgcct gcccctgatg caaaagtttc ccaaacaggt catggtgcgc
1320
atcttctcca
ccaaccaggg tgggttcatg ctgcctatct acgagacggc cgcgaaggcc
1380
tacgccgtgg
ggcagtttga gcagcccacc gagacccctc ccgaagacct ggacaccctg
1440
agcctggcca
tcgaggcagc catccaggac ctgaggaaca
agtctcag
1488
<210>
16
<211>
1488
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE2 VacO
H363A DNA sequence
<400>
16
atgggagaca
tcctagcaca agcagtgaac catgctggaa ttgactcatc
ttcgaccgga 60
ccaactctaa
cgactcattc atgttcggtt agttctgctc ctcttaacaa
gcctacacct 120
acctcggtag
ctgttaccaa cacaccttta ccaggagcat cagcaacacc
tgagttgtct 180
ccaagaaaga
agcctcgtaa gaccacgaga ccgttcaagg tgatcatcaa
gccaccagta 240
ccacctgctc
cgatcatgtt gccattgatc aagcaggagg acattaagcc
agaacctgac 300
ttcacgatac
agtaccgtaa caagatcata gatacagcag gatgcatagt
gatctcagat 360
agtgaagagg
agcaaggtga ggaagtggag actagaggag ccacagccag
ttcgccttcc 420
acaggatccg
gaactcctag agtaactagt ccgacacatc cactttccca
gatgaatcat 480
ccacctctac
cggatcctct aggacgacca gatgaagatt cttcttcatc
tagttcaagt 540
tcttgctcat
ccgcgagtga tagtgagtca gaaagtgaag agatgaagtg
ctcttctggt 600
ggtggagcta
gtgtcacttc atctcatcat ggacgaggag gatttggagg
tgctgcgagt 660
agttccttac
taagttgtgg acatcagtca tctggtggtg catctactgg
acctagaaag 720
aagaagtcaa
agagaatctc cgaattggat aatgagaaag tgagaaacat
catgaaggac 780
aagaacacgc
cgttctgcac tccgaatgtt cagacgagaa gaggacgagt
gaagatagat 840
gaagtatcac
gaatgttcag aaacacaaat cgttctctag agtacaagaa
tcttccgttc 900
accatacctt
cgatgcacca agtattagat gaggctatca aggcatgtaa
gaccatgcaa 960
gttaacaaca
aaggaataca gatcatctac actagaaacc atgaggttaa gagtgaggtg
1020
gatgccgtac
gttgtagatt gggaacgatg tgtaaccttg cgctatctac tcctttccta
1080
atggaggcta
ctatgcctgt gactcatcct cctgaagtgg ctcaaagaac agctgatgct
1140
tgtaacgaag
gtgtgaaagc tgcttggtcc ctaaaggagt tacatacaca ccaactttgt
1200
ccacgatcca
gtgactacag aaacatgatc attcatgcag ctacgcctgt agatctactt
1260
ggagctctta
acctatgtct tcctttgatg cagaagttcc ctaagcaagt gatggtgaga
1320
atcttctcga
cgaatcaagg aggattcatg ttaccgatat acgagacagc tgcaaaggct
1380
tacgctgtcg
gtcagttcga gcaaccgact gaaacgcctc ctgaggactt agatacattg
1440
tctttggcga
tagaagcagc gattcaggat cttagaaaca
agagtcag
1488
<210>
17
<211>
1488
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE2 VacO
H369A DNA sequence
<400>
17
atgggagaca
tcctagcaca agcagtgaac catgctggaa ttgactcatc
ttcgaccgga 60
ccaactctaa
cgactcattc atgttcggtt agttctgctc ctcttaacaa
gcctacacct 120
acctcggtag
ctgttaccaa cacaccttta ccaggagcat cagcaacacc
tgagttgtct 180
ccaagaaaga agcctcgtaa
gaccacgaga ccgttcaagg tgatcatcaa gccaccagta 240
ccacctgctc
cgatcatgtt gccattgatc aagcaggagg acattaagcc
agaacctgac 300
ttcacgatac
agtaccgtaa caagatcata gatacagcag gatgcatagt
gatctcagat 360
agtgaagagg
agcaaggtga ggaagtggag actagaggag ccacagccag
ttcgccttcc 420
acaggatccg
gaactcctag agtaactagt ccgacacatc cactttccca
gatgaatcat 480
ccacctctac
cggatcctct aggacgacca gatgaagatt cttcttcatc
tagttcaagt 540
tcttgctcat
ccgcgagtga tagtgagtca gaaagtgaag agatgaagtg ctcttctggt 600
ggtggagcta
gtgtcacttc atctcatcat ggacgaggag gatttggagg
tgctgcgagt 660
agttccttac
taagttgtgg acatcagtca tctggtggtg catctactgg
acctagaaag 720
aagaagtcaa
agagaatctc cgaattggat aatgagaaag tgagaaacat
catgaaggac 780
aagaacacgc
cgttctgcac tccgaatgtt cagacgagaa gaggacgagt
gaagatagat 840
gaagtatcac
gaatgttcag aaacacaaat cgttctctag agtacaagaa
tcttccgttc 900
accatacctt
cgatgcacca agtattagat gaggctatca aggcatgtaa
gaccatgcaa 960
gttaacaaca
aaggaataca gatcatctac actagaaacc atgaggttaa gagtgaggtg
1020
gatgccgtac
gttgtagatt gggaacgatg tgtaaccttg cgctatctac tcctttccta
1080
atggagcata
ctatgcctgt gactgctcct cctgaagtgg ctcaaagaac agctgatgct
1140
tgtaacgaag
gtgtgaaagc tgcttggtcc ctaaaggagt tacatacaca ccaactttgt
1200
ccacgatcca
gtgactacag aaacatgatc attcatgcag ctacgcctgt agatctactt
1260
ggagctctta
acctatgtct tcctttgatg cagaagttcc ctaagcaagt gatggtgaga
1320
atcttctcga
cgaatcaagg aggattcatg ttaccgatat acgagacagc tgcaaaggct
1380
tacgctgtcg
gtcagttcga gcaaccgact gaaacgcctc ctgaggactt agatacattg
1440
tctttggcga
tagaagcagc gattcaggat cttagaaaca
agagtcag
1488
<210>
18
<211>
1488
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE2 VacO
H363A/H369A DNA sequence
<400>
18
atgggagaca
tcctagcaca agcagtgaac catgctggaa ttgactcatc
ttcgaccgga 60
ccaactctaa
cgactcattc atgttcggtt agttctgctc ctcttaacaa
gcctacacct 120
acctcggtag
ctgttaccaa cacaccttta ccaggagcat cagcaacacc tgagttgtct
180
ccaagaaaga
agcctcgtaa gaccacgaga ccgttcaagg tgatcatcaa
gccaccagta 240
ccacctgctc
cgatcatgtt gccattgatc aagcaggagg acattaagcc
agaacctgac 300
ttcacgatac
agtaccgtaa caagatcata gatacagcag gatgcatagt
gatctcagat 360
agtgaagagg
agcaaggtga ggaagtggag actagaggag ccacagccag
ttcgccttcc 420
acaggatccg
gaactcctag agtaactagt ccgacacatc cactttccca
gatgaatcat 480
ccacctctac
cggatcctct aggacgacca gatgaagatt cttcttcatc
tagttcaagt 540
tcttgctcat
ccgcgagtga tagtgagtca gaaagtgaag agatgaagtg
ctcttctggt 600
ggtggagcta
gtgtcacttc atctcatcat ggacgaggag gatttggagg
tgctgcgagt 660
agttccttac
taagttgtgg acatcagtca tctggtggtg catctactgg
acctagaaag 720
aagaagtcaa
agagaatctc cgaattggat aatgagaaag tgagaaacat catgaaggac
780
aagaacacgc
cgttctgcac tccgaatgtt cagacgagaa gaggacgagt
gaagatagat 840
gaagtatcac
gaatgttcag aaacacaaat cgttctctag agtacaagaa
tcttccgttc 900
accatacctt
cgatgcacca agtattagat gaggctatca aggcatgtaa
gaccatgcaa 960
gttaacaaca
aaggaataca gatcatctac actagaaacc atgaggttaa gagtgaggtg
1020
gatgccgtac
gttgtagatt gggaacgatg tgtaaccttg cgctatctac tcctttccta
1080
atggaggcta
ctatgcctgt gactgctcct cctgaagtgg ctcaaagaac agctgatgct
1140
tgtaacgaag
gtgtgaaagc tgcttggtcc ctaaaggagt tacatacaca ccaactttgt
1200
ccacgatcca
gtgactacag aaacatgatc attcatgcag ctacgcctgt agatctactt
1260
ggagctctta
acctatgtct tcctttgatg cagaagttcc ctaagcaagt gatggtgaga
1320
atcttctcga
cgaatcaagg aggattcatg ttaccgatat acgagacagc tgcaaaggct
1380
tacgctgtcg
gtcagttcga gcaaccgact gaaacgcctc ctgaggactt agatacattg
1440
tctttggcga
tagaagcagc gattcaggat cttagaaaca
agagtcag
1488
<210>
19
<211>
496
<212>
PRT
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polypeptide IE2-VacO amino
acid sequence
<400>
19
Met Gly Asp
Ile Leu Ala Gln Ala Val Asn His Ala Gly Ile Asp Ser
1
5
10
15
Ser Ser Thr
Gly Pro Thr Leu Thr Thr His Ser Cys Ser Val Ser Ser
20
25
30
Ala Pro Leu
Asn Lys Pro Thr Pro Thr Ser Val Ala Val Thr Asn Thr
35
40
45
Pro Leu Pro
Gly Ala Ser Ala Thr Pro Glu Leu Ser Pro Arg Lys Lys
50
55
60
Pro Arg
Lys Thr Thr Arg Pro Phe Lys Val Ile Ile Lys Pro Pro Val
65
70
75
80
Pro Pro
Ala Pro Ile Met Leu Pro Leu Ile Lys Gln Glu Asp Ile Lys
85
90
95
Pro Glu
Pro Asp Phe Thr Ile Gln Tyr Arg Asn Lys Ile Ile Asp Thr
100
105
110
Ala Gly Cys
Ile Val Ile Ser Asp Ser Glu Glu Glu Gln Gly Glu Glu
115
120
125
Val Glu Thr
Arg Gly Ala Thr Ala Ser Ser Pro Ser Thr Gly Ser Gly
130
135
140
Thr Pro
Arg Val Thr Ser Pro Thr His Pro Leu Ser Gln Met Asn His
145
150
155
160
Pro Pro Leu
Pro Asp Pro Leu Gly Arg Pro Asp Glu Asp Ser Ser Ser
165
170
175
Ser Ser Ser Ser
Ser Cys Ser Ser Ala Ser Asp Ser Glu Ser Glu Ser
180
185
190
Glu Glu Met
Lys Cys Ser Ser Gly Gly Gly Ala Ser Val Thr Ser Ser
195
200
205
His His
Gly Arg Gly Gly Phe Gly Gly Ala Ala Ser Ser Ser Leu Leu
210
215
220
Ser Cys
Gly His Gln Ser Ser Gly Gly Ala Ser Thr Gly Pro Arg Lys
225
230
235
240
Lys Lys
Ser Lys Arg Ile Ser Glu Leu Asp Asn Glu Lys Val Arg Asn
245
250
255
Ile Met
Lys Asp Lys Asn Thr Pro Phe Cys Thr Pro Asn Val Gln Thr
260
265
270
Arg Arg
Gly Arg Val Lys Ile Asp Glu Val Ser Arg Met Phe Arg Asn
275
280
285
Thr Asn
Arg Ser Leu Glu Tyr Lys Asn Leu Pro Phe Thr Ile Pro Ser
290
295
300
Met His
Gln Val Leu Asp Glu Ala Ile Lys Ala Cys Lys Thr Met Gln
305
310
315
320
Val Asn
Asn Lys Gly Ile Gln Ile Ile Tyr Thr Arg Asn His Glu Val
325
330
335
Lys Ser
Glu Val Asp Ala Val Arg Cys Arg Leu Gly Thr Met Cys Asn
340
345
350
Leu Ala
Leu Ser Thr Pro Phe Leu Met Glu His Thr Met Pro Val Thr
355
360
365
His Pro
Pro Glu Val Ala Gln Arg Thr Ala Asp Ala Cys Asn Glu Gly
370
375
380
Val Lys
Ala Ala Trp Ser Leu Lys Glu Leu His Thr His Gln Leu Cys
385
390
395
400
Pro Arg
Ser Ser Asp Tyr Arg Asn Met Ile Ile His Ala Ala Thr Pro
405
410
415
Val Asp
Leu Leu Gly Ala Leu Asn Leu Cys Leu Pro Leu Met Gln Lys
420
425
430
Phe Pro
Lys Gln Val Met Val Arg Ile Phe Ser Thr Asn Gln Gly Gly
435
440
445
Phe Met Leu
Pro Ile Tyr Glu Thr Ala Ala Lys Ala Tyr Ala Val Gly
450
455
460
Gln Phe Glu
Gln Pro Thr Glu Thr Pro Pro Glu Asp Leu Asp Thr Leu
465
470
475
480
Ser Leu Ala
Ile Glu Ala Ala Ile Gln Asp Leu Arg Asn Lys Ser Gln
485
490
495
<210>
20
<211>
496
<212>
PRT
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polypeptide IE2 amino acid sequence
<400>
20
Met Gly
Asp Ile Leu Ala Gln Ala Val Asn His Ala Gly Ile Asp Ser
1
5
10
15
Ser Ser
Thr Gly Pro Thr Leu Thr Thr His Ser Cys Ser Val Ser Ser
20
25
30
Ala Pro
Leu Asn Lys Pro Thr Pro Thr Ser Val Ala Val Thr Asn Thr
35
40
45
Pro Leu
Pro Gly Ala Ser Ala Thr Pro Glu Leu Ser Pro Arg Lys Lys
50
55
60
Pro Arg
Lys Thr Thr Arg Pro Phe Lys Val Ile Ile Lys Pro Pro Val
65
70
75
80
Pro Pro
Ala Pro Ile Met Leu Pro Leu Ile Lys Gln Glu Asp Ile Lys
85
90
95
Pro Glu
Pro Asp Phe Thr Ile Gln Tyr Arg Asn Lys Ile Ile Asp Thr
100
105
110
Ala Gly Cys
Ile Val Ile Ser Asp Ser Glu Glu Glu Gln Gly Glu Glu
115
120
125
Val Glu Thr
Arg Gly Ala Thr Ala Ser Ser Pro Ser Thr Gly Ser Gly
130
135
140
Thr Pro
Arg Val Thr Ser Pro Thr His Pro Leu Ser Gln Met Asn His
145
150
155 160
Pro Pro Leu
Pro Asp Pro Leu Gly Arg Pro Asp Glu Asp Ser Ser Ser
165
170
175
Ser Ser Ser
Ser Ser Cys Ser Ser Ala Ser Asp Ser Glu Ser Glu Ser
180
185 190
Glu Glu Met
Lys Cys Ser Ser Gly Gly Gly Ala Ser Val Thr Ser Ser
195
200
205
His His
Gly Arg Gly Gly Phe Gly Gly Ala Ala Ser Ser Ser Leu Leu
210
215 220
Ser Cys
Gly His Gln Ser Ser Gly Gly Ala Ser Thr Gly Pro Arg Lys
225
230
235
240
Lys Lys
Ser Lys Arg Ile Ser Glu Leu Asp Asn Glu Lys Val Arg Asn
245 250
255
Ile Met
Lys Asp Lys Asn Thr Pro Phe Cys Thr Pro Asn Val Gln Thr
260
265
270
Arg Arg
Gly Arg Val Lys Ile Asp Glu Val Ser Arg Met Phe Arg Asn
275 280
285
Thr Asn
Arg Ser Leu Glu Tyr Lys Asn Leu Pro Phe Thr Ile Pro Ser
290
295
300
Met His
Gln Val Leu Asp Glu Ala Ile Lys Ala Cys Lys Thr Met Gln
305
310
315
320
Val Asn
Asn Lys Gly Ile Gln Ile Ile Tyr Thr Arg Asn His Glu Val
325
330
335
Lys Ser
Glu Val Asp Ala Val Arg Cys Arg Leu Gly Thr Met Cys Asn
340
345
350
Leu Ala
Leu Ser Thr Pro Phe Leu Met Glu His Thr Met Pro Val Thr
355
360
365
His Pro
Pro Glu Val Ala Gln Arg Thr Ala Asp Ala Cys Asn Glu Gly
370
375
380
Val Lys
Ala Ala Trp Ser Leu Lys Glu Leu His Thr His Gln Leu Cys
385
390
395
400
Pro Arg
Ser Ser Asp Tyr Arg Asn Met Ile Ile His Ala Ala Thr Pro
405
410
415
Val Asp
Leu Leu Gly Ala Leu Asn Leu Cys Leu Pro Leu Met Gln Lys
420
425
430
Phe Pro
Lys Gln Val Met Val Arg Ile Phe Ser Thr Asn Gln Gly Gly
435
440
445
Phe Met Leu
Pro Ile Tyr Glu Thr Ala Ala Lys Ala Tyr Ala Val Gly
450
455
460
Gln Phe Glu
Gln Pro Thr Glu Thr Pro Pro Glu Asp Leu Asp Thr Leu
465
470
475
480
Ser Leu Ala
Ile Glu Ala Ala Ile Gln Asp Leu Arg Asn Lys Ser Gln
485
490
495
<210>
21
<211>
496
<212>
PRT
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polypeptide IE2-4nt amino acid sequence
<400>
21
Met Gly
Asp Ile Leu Ala Gln Ala Val Asn His Ala Gly Ile Asp Ser
1
5
10 15
Ser Ser
Thr Gly Pro Thr Leu Thr Thr His Ser Cys Ser Val Ser Ser
20
25
30
Ala Pro
Leu Asn Lys Pro Thr Pro Thr Ser Val Ala Val Thr Asn Thr
35
40 45
Pro Leu
Pro Gly Ala Ser Ala Thr Pro Glu Leu Ser Pro Arg Lys Lys
50
55
60
Pro Arg
Lys Thr Thr Arg Pro Phe Lys Val Ile Ile Lys Pro Pro Val
65
70 75
80
Pro Pro
Ala Pro Ile Met Leu Pro Leu Ile Lys Gln Glu Asp Ile Lys
85
90
95
Pro Glu
Pro Asp Phe Thr Ile Gln Tyr Arg Asn Lys Ile Ile Asp Thr
100
105
110
Ala Gly Cys
Ile Val Ile Ser Asp Ser Glu Glu Glu Gln Gly Glu Glu
115
120
125
Val Glu Thr
Arg Gly Ala Thr Ala Ser Ser Pro Ser Thr Gly Ser Gly
130
135
140
Thr Pro
Arg Val Thr Ser Pro Thr His Pro Leu Ser Gln Met Asn His
145
150
155
160
Pro Pro Leu
Pro Asp Pro Leu Gly Arg Pro Asp Glu Asp Ser Ser Ser
165
170
175
Ser Ser Ser
Ser Ser Cys Ser Ser Ala Ser Asp Ser Glu Ser Glu Ser
180
185
190
Glu Glu Met
Lys Cys Ser Ser Gly Gly Gly Ala Ser Val Thr Ser Ser
195
200
205
His His
Gly Arg Gly Gly Phe Gly Gly Ala Ala Ser Ser Ser Leu Leu
210
215
220
Ser Cys
Gly His Gln Ser Ser Gly Gly Ala Ser Thr Gly Pro Arg Lys
225
230
235
240
Lys Lys
Ser Lys Arg Ile Ser Glu Leu Asp Asn Glu Lys Val Arg Asn
245
250
255
Ile Met
Lys Asp Lys Asn Thr Pro Phe Cys Thr Pro Asn Val Gln Thr
260
265
270
Arg Arg
Gly Arg Val Lys Ile Asp Glu Val Ser Arg Met Phe Arg Asn
275
280
285
Thr Asn
Arg Ser Leu Glu Tyr Lys Asn Leu Pro Phe Thr Ile Pro Ser
290
295
300
Met His
Gln Val Leu Asp Glu Ala Ile Lys Ala Cys Lys Thr Met Gln
305
310
315
320
Val Asn
Asn Lys Gly Ile Gln Ile Ile Tyr Thr Arg Asn His Glu Val
325
330
335
Lys Ser
Glu Val Asp Ala Val Arg Cys Arg Leu Gly Thr Met Cys Asn
340
345
350
Leu Ala
Leu Ser Thr Pro Phe Leu Met Glu His Thr Met Pro Val Thr
355
360
365
His Pro
Pro Glu Val Ala Gln Arg Thr Ala Asp Ala Cys Asn Glu Gly
370
375
380
Val Lys
Ala Ala Trp Ser Leu Lys Glu Leu His Thr His Gln Leu Cys
385
390
395
400
Pro Arg
Ser Ser Asp Tyr Arg Asn Met Ile Ile His Ala Ala Thr Pro
405
410
415
Val Asp Leu
Leu Gly Ala Leu Asn Leu Cys Leu Pro Leu Met Gln Lys
420
425
430
Phe Pro
Lys Gln Val Met Val Arg Ile Phe Ser Thr Asn Gln Gly Gly
435
440
445
Phe Met Leu
Pro Ile Tyr Glu Thr Ala Ala Lys Ala Tyr Ala Val Gly
450
455
460
Gln Phe Glu
Gln Pro Thr Glu Thr Pro Pro Glu Asp Leu Asp Thr Leu
465
470
475
480
Ser Leu Ala
Ile Glu Ala Ala Ile Gln Asp Leu Arg Asn Lys Ser Gln
485
490
495
<210>
22
<211>
496
<212>
PRT
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polypeptide IE2 H363A amino acid sequence
<400>
22
Met Gly Asp
Ile Leu Ala Gln Ala Val Asn His Ala Gly Ile Asp Ser
1
5
10
15
Ser Ser Thr
Gly Pro Thr Leu Thr Thr His Ser Cys Ser Val Ser Ser
20
25
30
Ala Pro Leu
Asn Lys Pro Thr Pro Thr Ser Val Ala Val Thr Asn Thr
35
40
45
Pro Leu Pro
Gly Ala Ser Ala Thr Pro Glu Leu Ser Pro Arg Lys Lys
50
55
60
Pro Arg
Lys Thr Thr Arg Pro Phe Lys Val Ile Ile Lys Pro Pro Val
65
70
75
80
Pro Pro
Ala Pro Ile Met Leu Pro Leu Ile Lys Gln Glu Asp Ile Lys
85
90
95
Pro Glu
Pro Asp Phe Thr Ile Gln Tyr Arg Asn Lys Ile Ile Asp Thr
100
105
110
Ala Gly Cys
Ile Val Ile Ser Asp Ser Glu Glu Glu Gln Gly Glu Glu
115
120
125
Val Glu Thr
Arg Gly Ala Thr Ala Ser Ser Pro Ser Thr Gly Ser Gly
130
135
140
Thr Pro
Arg Val Thr Ser Pro Thr His Pro Leu Ser Gln Met Asn His
145
150
155
160
Pro Pro Leu
Pro Asp Pro Leu Gly Arg Pro Asp Glu Asp Ser Ser Ser
165
170
175
Ser Ser Ser
Ser Ser Cys Ser Ser Ala Ser Asp Ser Glu Ser Glu Ser
180
185
190
Glu Glu Met
Lys Cys Ser Ser Gly Gly Gly Ala Ser Val Thr Ser Ser
195
200
205
His His
Gly Arg Gly Gly Phe Gly Gly Ala Ala Ser Ser Ser Leu Leu
210
215
220
Ser Cys
Gly His Gln Ser Ser Gly Gly Ala Ser Thr Gly Pro Arg Lys
225
230
235
240
Lys Lys
Ser Lys Arg Ile Ser Glu Leu Asp Asn Glu Lys Val Arg Asn
245
250
255
Ile Met
Lys Asp Lys Asn Thr Pro Phe Cys Thr Pro Asn Val Gln Thr
260
265
270
Arg Arg
Gly Arg Val Lys Ile Asp Glu Val Ser Arg Met Phe Arg Asn
275
280
285
Thr Asn
Arg Ser Leu Glu Tyr Lys Asn Leu Pro Phe Thr Ile Pro Ser
290
295
300
Met His
Gln Val Leu Asp Glu Ala Ile Lys Ala Cys Lys Thr Met Gln
305
310
315
320
Val Asn
Asn Lys Gly Ile Gln Ile Ile Tyr Thr Arg Asn His Glu Val
325
330
335
Lys Ser
Glu Val Asp Ala Val Arg Cys Arg Leu Gly Thr Met Cys Asn
340
345
350
Leu Ala
Leu Ser Thr Pro Phe Leu Met Glu Ala Thr Met Pro Val Thr
355
360
365
His Pro
Pro Glu Val Ala Gln Arg Thr Ala Asp Ala Cys Asn Glu Gly
370
375
380
Val Lys
Ala Ala Trp Ser Leu Lys Glu Leu His Thr His Gln Leu Cys
385
390
395
400
Pro Arg
Ser Ser Asp Tyr Arg Asn Met Ile Ile His Ala Ala Thr Pro
405
410
415
Val Asp
Leu Leu Gly Ala Leu Asn Leu Cys Leu Pro Leu Met Gln Lys
420
425
430
Phe Pro
Lys Gln Val Met Val Arg Ile Phe Ser Thr Asn Gln Gly Gly
435
440
445
Phe Met Leu
Pro Ile Tyr Glu Thr Ala Ala Lys Ala Tyr Ala Val Gly
450
455
460
Gln Phe Glu
Gln Pro Thr Glu Thr Pro Pro Glu Asp Leu Asp Thr Leu
465
470
475
480
Ser Leu Ala
Ile Glu Ala Ala Ile Gln Asp Leu Arg Asn Lys Ser Gln
485
490
495
<210>
23
<211>
496
<212>
PRT
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polypeptide IE2 H369A amino
acid sequence
<400>
23
Met Gly Asp
Ile Leu Ala Gln Ala Val Asn His Ala Gly Ile Asp Ser
1
5
10
15
Ser Ser Thr
Gly Pro Thr Leu Thr Thr His Ser Cys Ser Val Ser Ser
20
25
30
Ala Pro Leu
Asn Lys Pro Thr Pro Thr Ser Val Ala Val Thr Asn Thr
35
40
45
Pro Leu Pro
Gly Ala Ser Ala Thr Pro Glu Leu Ser Pro Arg Lys Lys
50
55
60
Pro Arg
Lys Thr Thr Arg Pro Phe Lys Val Ile Ile Lys Pro Pro Val
65
70
75
80
Pro Pro
Ala Pro Ile Met Leu Pro Leu Ile Lys Gln Glu Asp Ile Lys
85
90
95
Pro Glu Pro
Asp Phe Thr Ile Gln Tyr Arg Asn Lys Ile Ile Asp Thr
100
105
110
Ala Gly Cys
Ile Val Ile Ser Asp Ser Glu Glu Glu Gln Gly Glu Glu
115
120
125
Val Glu Thr
Arg Gly Ala Thr Ala Ser Ser Pro Ser Thr Gly Ser Gly
130
135
140
Thr Pro
Arg Val Thr Ser Pro Thr His Pro Leu Ser Gln Met Asn His
145
150
155
160
Pro Pro Leu
Pro Asp Pro Leu Gly Arg Pro Asp Glu Asp Ser Ser Ser
165
170
175
Ser Ser Ser
Ser Ser Cys Ser Ser Ala Ser Asp Ser Glu Ser Glu Ser
180
185
190
Glu Glu Met
Lys Cys Ser Ser Gly Gly Gly Ala Ser Val Thr Ser Ser
195
200
205
His His
Gly Arg Gly Gly Phe Gly Gly Ala Ala Ser Ser Ser Leu Leu
210
215
220
Ser Cys
Gly His Gln Ser Ser Gly Gly Ala Ser Thr Gly Pro Arg Lys
225
230
235
240
Lys Lys
Ser Lys Arg Ile Ser Glu Leu Asp Asn Glu Lys Val Arg Asn
245
250
255
Ile Met
Lys Asp Lys Asn Thr Pro Phe Cys Thr Pro Asn Val Gln Thr
260
265
270
Arg Arg
Gly Arg Val Lys Ile Asp Glu Val Ser Arg Met Phe Arg Asn
275
280
285
Thr Asn
Arg Ser Leu Glu Tyr Lys Asn Leu Pro Phe Thr Ile Pro Ser
290
295
300
Met His
Gln Val Leu Asp Glu Ala Ile Lys Ala Cys Lys Thr Met Gln
305
310
315
320
Val Asn
Asn Lys Gly Ile Gln Ile Ile Tyr Thr Arg Asn His Glu Val
325
330
335
Lys Ser
Glu Val Asp Ala Val Arg Cys Arg Leu Gly Thr Met Cys Asn
340
345
350
Leu Ala
Leu Ser Thr Pro Phe Leu Met Glu His Thr Met Pro Val Thr
355
360
365
Ala Pro Pro
Glu Val Ala Gln Arg Thr Ala Asp Ala Cys Asn Glu Gly
370
375
380
Val Lys Ala
Ala Trp Ser Leu Lys Glu Leu His Thr His Gln Leu Cys
385
390
395
400
Pro Arg Ser
Ser Asp Tyr Arg Asn Met Ile Ile His Ala Ala Thr Pro
405
410
415
Val Asp Leu
Leu Gly Ala Leu Asn Leu Cys Leu Pro Leu Met Gln Lys
420
425
430
Phe Pro
Lys Gln Val Met Val Arg Ile Phe Ser Thr Asn Gln Gly Gly
435
440
445
Phe Met Leu
Pro Ile Tyr Glu Thr Ala Ala Lys Ala Tyr Ala Val Gly
450
455
460
Gln Phe Glu
Gln Pro Thr Glu Thr Pro Pro Glu Asp Leu Asp Thr Leu
465
470
475
480
Ser Leu Ala
Ile Glu Ala Ala Ile Gln Asp Leu Arg Asn Lys Ser Gln
485
490
495
<210>
24
<211>
496
<212>
PRT
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polypeptide IE2 H363A/H369A
amino acid sequence
<400>
24
Met Gly Asp
Ile Leu Ala Gln Ala Val Asn His Ala Gly Ile Asp Ser
1
5
10 15
Ser Ser Thr
Gly Pro Thr Leu Thr Thr His Ser Cys Ser Val Ser Ser
20
25
30
Ala Pro Leu
Asn Lys Pro Thr Pro Thr Ser Val Ala Val Thr Asn Thr
35
40 45
Pro Leu Pro
Gly Ala Ser Ala Thr Pro Glu Leu Ser Pro Arg Lys Lys
50
55
60
Pro Arg
Lys Thr Thr Arg Pro Phe Lys Val Ile Ile Lys Pro Pro Val
65
70 75
80
Pro Pro
Ala Pro Ile Met Leu Pro Leu Ile Lys Gln Glu Asp Ile Lys
85
90
95
Pro Glu
Pro Asp Phe Thr Ile Gln Tyr Arg Asn Lys Ile Ile Asp Thr
100
105
110
Ala Gly Cys
Ile Val Ile Ser Asp Ser Glu Glu Glu Gln Gly Glu Glu
115
120
125
Val Glu Thr
Arg Gly Ala Thr Ala Ser Ser Pro Ser Thr Gly Ser Gly
130
135
140
Thr Pro
Arg Val Thr Ser Pro Thr His Pro Leu Ser Gln Met Asn His
145
150
155
160
Pro Pro Leu
Pro Asp Pro Leu Gly Arg Pro Asp Glu Asp Ser Ser Ser
165
170
175
Ser Ser Ser
Ser Ser Cys Ser Ser Ala Ser Asp Ser Glu Ser Glu Ser
180
185
190
Glu Glu Met
Lys Cys Ser Ser Gly Gly Gly Ala Ser Val Thr Ser Ser
195
200
205
His His
Gly Arg Gly Gly Phe Gly Gly Ala Ala Ser Ser Ser Leu Leu
210
215
220
Ser Cys
Gly His Gln Ser Ser Gly Gly Ala Ser Thr Gly Pro Arg Lys
225
230
235
240
Lys Lys
Ser Lys Arg Ile Ser Glu Leu Asp Asn Glu Lys Val Arg Asn
245
250
255
Ile Met
Lys Asp Lys Asn Thr Pro Phe Cys Thr Pro Asn Val Gln Thr
260
265
270
Arg Arg
Gly Arg Val Lys Ile Asp Glu Val Ser Arg Met Phe Arg Asn
275
280
285
Thr Asn
Arg Ser Leu Glu Tyr Lys Asn Leu Pro Phe Thr Ile Pro Ser
290
295
300
Met His
Gln Val Leu Asp Glu Ala Ile Lys Ala Cys Lys Thr Met Gln
305
310
315
320
Val Asn
Asn Lys Gly Ile Gln Ile Ile Tyr Thr Arg Asn His Glu Val
325
330
335
Lys Ser
Glu Val Asp Ala Val Arg Cys Arg Leu Gly Thr Met Cys Asn
340
345
350
Leu Ala
Leu Ser Thr Pro Phe Leu Met Glu Ala Thr Met Pro Val Thr
355
360
365
Ala Pro
Pro Glu Val Ala Gln Arg Thr Ala Asp Ala Cys Asn Glu Gly
370
375
380
Val Lys
Ala Ala Trp Ser Leu Lys Glu Leu His Thr His Gln Leu Cys
385
390
395
400
Pro Arg
Ser Ser Asp Tyr Arg Asn Met Ile Ile His Ala Ala Thr Pro
405
410
415
Val Asp Leu
Leu Gly Ala Leu Asn Leu Cys Leu Pro Leu Met Gln Lys
420
425
430
Phe Pro
Lys Gln Val Met Val Arg Ile Phe Ser Thr Asn Gln Gly Gly
435
440
445
Phe Met Leu
Pro Ile Tyr Glu Thr Ala Ala Lys Ala Tyr Ala Val Gly
450
455
460
Gln Phe Glu
Gln Pro Thr Glu Thr Pro Pro Glu Asp Leu Asp Thr Leu
465
470
475
480
Ser Leu Ala
Ile Glu Ala Ala Ile Gln Asp Leu Arg Asn Lys Ser Gln
485
490
495
<210>
25
<400>
25
000
<210>
26
<400>
26
000
<210>
27
<211>
1224
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE1 VacO
<400>
27
atggtgaagc
aaatcaaggt cagagtggac atggtaagac acagaattaa
ggaacacatg 60
ttgaagaagt
atactcaaac agaggagaag ttcaccggtg ccttcaatat
gatgggtgga 120
tgtctacaga
acgctttgga tatcttagat aaggtacatg aaccattcga
agaaatgaag 180
tgcattggat
tgacaatgca atcaatgtat gagaactaca tagtgccaga
ggataagcgt 240
gaaatgtgga
tggcatgcat caaggagtta catgatgtat ccaaaggagc
agccaacaag 300
ctaggtggtg
ctttgcaagc gaaggcaaga gcgaagaagg atgaattgag
acgaaagatg 360
atgtacatgt
gctatcgaaa catcgaattc ttcactaaga actcagcgtt
tcctaagact 420
accaatggat
gcagtcaagc tatggctgcg cttcagaact tgcctcaatg
tagtcctgat 480
gaaatcatgg
catatgcaca gaagatcttc aagatcttag atgaggaaag
agacaaggta 540
ttgactcata
tcgatcacat attcatggat atactaacaa catgtgtaga
aacgatgtgt 600
aacgagtaca
aggtaacttc ggacgcttgt atgatgacta tgtacggagg
aatatctcta 660
cttagtgagt
tctgtcgagt tctatgctgt tacgtattag aagaaactag
tgtaatgtta 720
gcgaagagac
cattgatcac taagcctgaa gtgatctcgg ttatgaagag
acgaatagag 780
gagatctgta
tgaaggtgtt cgcacaatac atcttaggag ctgatcctct
aagagtgtgt 840
agtccatcgg
tagacgattt gagagctata gcggaggaat ctgacgagga
agaggcaata 900
gttgcataca
cacttgctac agctggagta tccagttctg attctcttgt
aagtcctccg 960
gagtcacctg
tgccagcaac cataccgttg agtagtgtga ttgtggctga gaactcggat
1020
caggaagagt
ctgagcaatc cgatgaagaa gaggaggaag gagcacaaga ggagagagaa
1080
gatactgtct
ctgtgaagag tgaacctgta tctgaaatcg aggaagtagc acctgaggaa
1140
gaggaggatg
gagccgaaga accaacagct tcgggtggta agtcaactca tccgatggta
1200
accagatcta
aggcagacca
gtaa
1224
<210>
28
<211>
1194
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE1
<400>
28
atggtgcggc
atagaatcaa ggagcacatg ctgaaaaaat atacccagac
ggaagagaaa 60
ttcactggcg
cctttaatat gatgggagga tgtttgcaga atgccttaga
tatcttagat 120
aaggttcatg
agcctttcga ggagatgaag tgtattgggc taactatgca gagcatgtat
180
gagaactaca
ttgtacctga ggataagcgg gagatgtgga tggcttgtat
taaggagctg 240
catgatgtga
gcaagggcgc cgctaacaag ttggggggtg cactgcaggc
taaggcccgt 300
gctaaaaagg
atgaacttag gagaaagatg atgtatatgt gctacaggaa
tatagagttc 360
tttaccaaga
actcagcctt ccctaagacc accaatggct gcagtcaggc
catggcggca 420
ctgcagaact
tgcctcagtg ctcccctgat gagattatgg cttatgccca
gaaaatattt 480
aagattttgg
atgaggagag agacaaggtg ctcacgcaca ttgatcacat
atttatggat 540
atcctcacta
catgtgtgga aacaatgtgt aatgagtaca aggtcactag
tgacgcttgt 600
atgatgacca
tgtacggggg catctctctc ttaagtgagt tctgtcgggt
gctgtgctgc 660
tatgtcttag
aggagactag tgtgatgctg gccaagcggc ctctgataac
caagcctgag 720
gttatcagtg
taatgaagcg ccgcattgag gagatctgca tgaaggtctt tgcccagtac 780
attctggggg
ccgatcctct gagagtctgc tctcctagtg tggatgacct
acgggccatc 840
gccgaggagt
cagatgagga agaggctatt gtagcctaca ctttggccac
cgctggtgtc 900
agctcctctg
attctctggt gtcaccccca gagtcccctg tacccgcgac
tatccctctg 960
tcctcagtaa
ttgtggctga gaacagtgat caggaagaaa gtgagcagag tgatgaggaa
1020
gaggaggagg
gtgctcagga ggagcgggag gacactgtgt ctgtcaagtc tgagccagtg
1080
tctgagatag
aggaagttgc cccagaggaa gaggaggatg gtgctgagga acccaccgcc
1140
tctggaggca
agagcaccca ccctatggtg actagaagca aggctgacca
gtaa 1194
<210>
29
<211>
1224
<212>
DNA
<213>
Artificial Sequence
<220>
<223>
Description of Artificial Sequence: Synthetic
polynucleotide IE1-4nt
<400>
29
atggtcaaac
agattaaggt tcgagtggac atggtgcggc atagaatcaa
ggagcacatg 60
ctgaagaagt
atacccagac ggaagagaaa ttcactggcg cctttaatat
gatgggagga 120
tgtttgcaga
atgccttaga tatcttagat aaggttcatg agcctttcga
ggagatgaag 180
tgtattgggc
taactatgca gagcatgtat gagaactaca ttgtacctga
ggataagcgg 240
gagatgtgga
tggcttgtat taaggagctg catgatgtga gcaagggcgc
cgctaacaag 300
ttaggaggtg
cactgcaggc taaggcccgt gctaagaagg atgaacttag
gagaaagatg 360
atgtatatgt
gctacaggaa tatagagttc tttaccaaga actcagcctt
ccctaagacc 420
accaatggct
gcagtcaggc catggcggca ctgcagaact tgcctcagtg
ctctcctgat 480
gagattatgg
cttatgccca gaagatattt aagatcttgg atgaggagag
agacaaggtg 540
ctcacgcaca
ttgatcacat atttatggat atcctcacta catgtgtgga
aacaatgtgt 600
aatgagtaca
aggtcactag tgacgcttgt atgatgacca tgtacggagg
catctctctc 660
ttaagtgagt
tctgtcgggt gctgtgctgc tatgtcttag aggagactag
tgtgatgctg 720
gccaagcggc
ctctgataac caagcctgag gttatcagtg taatgaagcg
ccgcattgag 780
gagatctgca
tgaaggtctt tgcccagtac attctaggtg ccgatcctct
gagagtctgc 840
tctcctagtg
tggatgacct acgggccatc gccgaggagt cagatgagga
agaggctatt 900
gtagcctaca
ctttggccac cgctggtgtc agctcctctg attctctggt
gtcacctcca 960
gagtcacctg
tacccgcgac tatccctctg tcctcagtaa ttgtggctga gaacagtgat
1020
caggaagaaa
gtgagcagag tgatgaggaa gaggaggagg gtgctcagga ggagcgggag
1080
gacactgtgt
ctgtcaagtc tgagccagtg tctgagatag aggaagttgc tccagaggaa
1140
gaggaggatg
gtgctgagga acccaccgcc tctggaggca agagcaccca ccctatggtg
1200
actagaagca
aggctgacca
gtaa
1224
Claims (20)
- 2つ以上のCMV抗原又はその抗原性部分をコードする2つ以上の核酸配列が挿入された遺伝子改変組換えワクシニアアンカラ(rMVA)ベクターを含む、2つ以上のサイトメガロウイルス(CMV)抗原を共発現させるための発現システムであって、ここで、前記CMV抗原又はその抗原性フラグメントは、IE1エクソン4(IE1/e4)、IE2エクソン5(IE2/e5)、IEfusion、及びpp65を包含し、且つここで、前記2つ以上の核酸配列は、044L/045L、IGR3、G1L/I8R、及びDel3から選択される1つ以上の挿入部位に挿入される、発現系。
- 前記2つ以上の核酸配列が、単一のプロモーターに作動可能に連結され、且つ単一のプロモーターの制御下にある、請求項1に記載の発現系。
- 前記プロモーターがmH5プロモーターである、請求項2に記載の発現系。
- 同じアミノ酸を発現しながら、連続するシトシン又はグアニンを除去するために1つ又は複数の核酸配列がコドン最適化されている、請求項1〜3のいずれか一項に記載の発現系。
- 前記CMV抗原のアミノ酸配列が、ウイルス継代時の前記rMVAの遺伝的安定性を改善するための1つ又は複数の突然変異を含む、請求項1から4のいずれか一項に記載の発現系。
- IE1及びIE2又はそれらの抗原性フラグメントがIE融合タンパク質として発現される、請求項1から5のいずれか一項に記載の発現系。
- 前記CMV抗原を発現する前記rMVAが少なくとも10継代にわたって遺伝的に安定である、請求項1から6のいずれか一項に記載の発現系。
- 2つ以上のCMV抗原又はその抗原部分をコードする2つ以上の核酸配列が挿入された、免疫学的に有効な量の組換え改変ワクシニアアンカラ(rMVA)ベクターを含むワクチン組成物であって、ここで、前記CMV抗原又はその抗原性フラグメントには、IE1エクソン4(IE1/e4)、IE2エクソン5(IE2/e5)、IEfusion、及びpp65を包含し、且つここで、前記2つ以上の核酸配列は、044L/045L、IGR3、G1L/I8R、及びDel3から選択される1つ以上の挿入部位に挿入される、ワクチン組成物。
- 前記2つ以上の核酸配列が、単一のプロモーターに作動可能に連結され、且つ単一のプロモーターの制御下にある、請求項8に記載のワクチン組成物。
- 前記プロモーターがmH5プロモーターである、請求項9に記載のワクチン組成物。
- 1つ又は複数の核酸配列が、同じアミノ酸を発現しながら連続するシトシン又はグアニンを除去するようにコドン最適化されている、請求項8から10のいずれか一項に記載のワクチン組成物。
- 前記CMV抗原のアミノ酸配列が、ウイルス継代時の前記rMVAの遺伝的安定性を改善するための1つ又は複数の突然変異を含む、請求項8から11のいずれか一項に記載のワクチン組成物。
- IE1及びIE2又はそれらの抗原性フラグメントがIE融合タンパク質として発現される、請求項8から12のいずれか一項に記載のワクチン組成物。
- 前記CMV抗原を発現する前記rMVAが少なくとも10継代にわたって遺伝的に安定である、請求項8から13のいずれか一項に記載のワクチン組成物。
- 請求項8から14のいずれか一項に記載のワクチンを、それを必要とする対象に投与することにより、対象において免疫応答を誘発又は改変する方法。
- 前記対象が哺乳動物である、請求項15に記載の方法。
- 前記対象がヒトである、請求項15に記載の方法。
- 2つ以上のCMV抗原又はその抗原性フラグメントを発現するrMVAの安定性を改善する方法であって、
(1)前記CMV抗原又はその抗原性断片をコードする1つ又は複数の核酸配列を、044L/045L、IGR3、G1L/I8R、及びDel3を包含する1つ又は複数の挿入部位に挿入すること;
(2)前記CMV抗原をコードする前記核酸配列をコドン最適化すること;及び
(3)前記CMV抗原の前記アミノ酸配列に1つ又は複数の変異を導入すること;
からなる群から選択される1つ以上の改変を組み込むことによる方法。 - 前記CMV抗原又はその抗原性フラグメントが、IE1エクソン4(IE1/e4)、IE2エクソン5(IE2/e5)、IEfusion(例えば、IE1とIE2又はIE1/e4とIE2/e5の融合)、及びpp65を包含する、請求項18に記載の方法。
- 前記コドン最適化が、前記核酸配列から連続するシトシン又はグアニンを除去することを含む、請求項18に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862670656P | 2018-05-11 | 2018-05-11 | |
US62/670,656 | 2018-05-11 | ||
PCT/US2019/031866 WO2019217922A1 (en) | 2018-05-11 | 2019-05-10 | Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021523712A true JP2021523712A (ja) | 2021-09-09 |
JPWO2019217922A5 JPWO2019217922A5 (ja) | 2022-05-18 |
Family
ID=68467105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020563659A Pending JP2021523712A (ja) | 2018-05-11 | 2019-05-10 | 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ(rmva)ワクチン及びその調製方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210062221A1 (ja) |
EP (1) | EP3790578A4 (ja) |
JP (1) | JP2021523712A (ja) |
CN (1) | CN112512568A (ja) |
WO (1) | WO2019217922A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023201314A1 (en) | 2022-04-13 | 2023-10-19 | City Of Hope | Cmv-hiv specific chimeric antigen receptor t cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100316667A1 (en) * | 2009-06-05 | 2010-12-16 | Don Diamond | Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7501127B2 (en) * | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
US8326547B2 (en) * | 2009-10-07 | 2012-12-04 | Nanjingjinsirui Science & Technology Biology Corp. | Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm |
CN116376983A (zh) * | 2012-07-27 | 2023-07-04 | 希望之城 | 一种递送ul128复合体和预防cmv感染的mva疫苗 |
WO2018075813A1 (en) * | 2016-10-19 | 2018-04-26 | City Of Hope | Use of endogenous viral vaccine in chimeric antigen receptor t cell therapy |
-
2019
- 2019-05-10 WO PCT/US2019/031866 patent/WO2019217922A1/en active Application Filing
- 2019-05-10 CN CN201980046532.XA patent/CN112512568A/zh active Pending
- 2019-05-10 JP JP2020563659A patent/JP2021523712A/ja active Pending
- 2019-05-10 EP EP19800357.6A patent/EP3790578A4/en not_active Withdrawn
-
2020
- 2020-11-11 US US17/095,300 patent/US20210062221A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100316667A1 (en) * | 2009-06-05 | 2010-12-16 | Don Diamond | Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof |
Non-Patent Citations (3)
Title |
---|
BLOOD, 2017, VOL.129, NO.1, PP.114-125, JPN6023016830, ISSN: 0005052447 * |
VACCINE, 2010, VOL.28, PP.1547-1557, JPN6023016831, ISSN: 0005052448 * |
VIROLOGY, 2010, VOL.403, PP.155-162, JPN6023016829, ISSN: 0005052449 * |
Also Published As
Publication number | Publication date |
---|---|
EP3790578A1 (en) | 2021-03-17 |
EP3790578A4 (en) | 2022-04-06 |
US20210062221A1 (en) | 2021-03-04 |
CN112512568A (zh) | 2021-03-16 |
WO2019217922A1 (en) | 2019-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210196806A1 (en) | Shared antigens | |
JP2023123766A (ja) | アルファウイルス新生抗原ベクター | |
US8282935B2 (en) | Materials and methods relating to improved vaccination strategies | |
KR20190098147A (ko) | 신생항원의 바이러스성 전달 | |
CN111328420B (zh) | 用于预防和治疗微卫星不稳定(msi)癌症的基于共有肿瘤新抗原的通用疫苗 | |
JP7457733B2 (ja) | 改変アデノウイルス | |
EP1890724A2 (en) | Compositions for inducing an immune response | |
JP7486566B2 (ja) | 改良lamp構築物 | |
US20220125919A1 (en) | Alphavirus neoantigen vectors and interferon inhibitors | |
CN112351793A (zh) | 免疫检查点抑制剂共表达载体 | |
JP2021523712A (ja) | 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ(rmva)ワクチン及びその調製方法 | |
US20070104685A1 (en) | Synthetic gene encoding human carcinoembryonic antigen and uses thereof | |
KR20230006825A (ko) | 전염성 질병 항원 및 백신 | |
JP2020536489A (ja) | Hpvワクチン | |
Alharbi et al. | Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity | |
US20230381299A1 (en) | Vaccination of hematopoietic stem cell donors with cytomegalovirus triplex composition | |
JPWO2020243719A5 (ja) | ||
RU2803566C2 (ru) | Неоантигенные векторы на основе альфавируса | |
JP2006518202A (ja) | アカゲザル癌胎児性抗原、前記抗原をコードするヌクレオチド、及びその使用 | |
WO2023111861A1 (en) | Prostate cancer vaccines and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220510 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220510 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230509 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231205 |